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Resumo 
 
 
 
As vesículas extracelulares (EV), particularmente os exossomas, são atualmente alvo de 
intensa investigação. As EV são mediadores fisiológicos de comunicação intercelular que 
refletem o fenótipo das células que as secretam, e que têm a capacidade de modular o 
fenótipo das células alvo. Estas características das EV têm vindo a ser exploradas para 
diferentes aplicações, nomeadamente para o desenvolvimento de biomarcadores de 
diagnóstico e prognóstico de diferentes doenças, bem como para o desenvolvimento de novas 
terapias, em particular na área do cancro, mas também da medicina regenerativa. Vários 
estudos in vivo, e também alguns ensaios clínicos, têm vindo a usar EV como veículos de 
entrega de biomoléculas funcionais. Nestes estudos, EV nativas ou modificadas têm sido 
administradas através de diferentes vias. Os primeiros estudos em modelos animais e 
pacientes humanos com administração sistémica de EV demonstraram várias limitações na 
biodistribuição e retenção das EV administradas. Assim, foi colocada a hipótese de que a 
incorporação das EV em biomateriais capazes de funcionar como um sistema de entrega 
poderia constituir uma potencial solução para ultrapassar estas limitações, potenciando o uso 
eficaz das EV. Deste modo, esta tese teve como objetivo o desenvolvimento de um sistema de 
entrega de EV que permita a libertação local e controlada das mesmas para efeitos de 
regeneração óssea.  
No trabalho desta tese, começou-se por otimizar as condições de cultura de diferentes 
linhas celulares imunes humanas, THP-1, KG-1 e Jurkat, nomeadamente em relação à 
concentração de soro do meio de cultura, de forma a obter uma produção de EV com alto 
rendimento e com grande pureza. As EV produzidas foram caracterizados por microscopia 
electrónica de transmissão, “nanoparticle tracking analysis”, e “western blotting” para 
marcadores exossomais, o que permitiu demostrar que, para todas as linhas celulares 
testadas, a população de EV isolada era enriquecida em exossomas. No entanto, a linha 
celular KG-1 produziu os níveis mais elevados de EV, mantendo a viabilidade celular mesmo a 
concentrações de soro de 0.1 % (v/v), e por isso estas células foram selecionadas para a 
produção das EV utilizados para a otimização das condições de incorporação num sistema de 
entrega. 
O sistema de entrega construído consistiu numa matriz 3D em quitosano funcionalizada 
com camadas de quitosano (Ch) e poli-γ-ácido glutâmico (γ-PGA) misturado com EV, 
depositadas alternadamente num sistema layer-by-layer. A incorporação das EV no sistema de 
entrega foi observada por microscopia confocal de fluorescência, usando EV previamente 
marcadas com um corante fluorescente, mas não pôde ser confirmada por espectroscopia de 
infra-vermelhos. De seguida, o perfil de libertação das EV do sistema de entrega foi testado 
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in vitro através da análise dos sobrenadantes do ensaio de libertação por microscopia 
electrónica de transmissão, após 0, 12 e 24 h de incubação, tendo sido possível identificar EV 
nestes sobrenadantes concentrados, em particular às 12 e 24 h de libertação. A nível 
funcional, o sistema de entrega produzido e funcionalizado com EV foi testado para a sua 
capacidade em promover o recrutamento, bem como a diferenciação osteogénica e 
condrogénica, de células mesenquimais multipotentes/estaminais do estroma (MSC), 
responsáveis pela formação do osso. Através de ensaios de microscopia de vídeo em tempo 
real, foi possível demonstrar que as EV incorporadas no sistema de entrega promoveram um 
aumento significativo da motilidade das MSC. Para além disso, resultados de expressão génica 
nas MSC mostraram que o sistema de entrega funcionalizado com Ch e γ-PGA foi pro-
condrogénico, mas que a presença de EV não levou a aumentos significativos da diferenciação 
das MSC. 
Em conclusão, foi possível incorporar EV no sistema 3D layer-by-layer de Ch e γ-PGA 
desenvolvido, que se mantiveram funcionais após libertação. As EV secretadas pelas células 
KG-1 promoveram o recrutamento das MSC através do aumento da sua motilidade, tal como já 
descrito para EV de células dendríticas primárias, enquanto que o sistema de entrega 
funcionalizado com o Ch e γ-PGA promoveu per se a diferenciação condrogénica das MSC. Em 
conjunto, os resultados obtidos suportam um efeito favorável da incorporação das EV num 
sistema de libertação controlada, sobre as MSC, sugerindo que as EV podem ser mediadores 
quimiotáticos deste tipo celular para locais de lesão óssea, onde o sistema de entrega 
produzido pode estimular a sua diferenciação, promovendo a reparação e regeneração do 
tecido ósseo.  
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Abstract 
 
Extracellular vesicles (EV), in particular exosomes, are currently the subject of intense 
research. EV are natural mediators of intercellular communication, reflecting the phenotype 
of the secreting cell, and potentially modulating the phenotype of target cells. These 
characteristics of EV are being exploited for different applications, namely the discovery of 
biomarkers for disease diagnosis and prognosis, and the development of new therapies, 
particularly in the cancer field, but also in regenerative medicine. Several in vivo studies 
using EV as delivery carriers of active biomolecules have been reported, including a few 
human clinical trials. In these studies, different routes of EV administration and the use of 
natural or modified EV formulations have been reported. Pioneering studies have been 
uncovering several limitations in EV biodistribution and retention in animal models and human 
subjects, when these are administered systemically. Consequently, it was hypothesized that 
incorporation of EV in biomaterial delivery systems could contribute to overcome these 
limitations. Thus, this thesis aimed to develop an EV delivery system for local and sustained 
EV release, particularly for bone regeneration.  
For this thesis, cell culture conditions for different human immune cell lines, THP-1, KG-1 
and Jurkat cells, in terms of serum concentration in the media, were optimized, in order to 
obtain higher yields of EV production, and with higher purity. EV produced were 
characterized by transmission electron microscopy, nanoparticle tracking analysis and 
western blotting for exosomal protein markers, and found to be enriched in exosomes for all 
cell lines tested. However, it was the cell line KG-1 that produced EV at higher yields, while 
still maintaining high cell viability at serum concentrations of 0.1 % (v/v), and thus these cells 
were selected as EV producers for further use in optimizing the incorporation into a delivery 
system. 
The EV delivery systems developed consisted of chitosan 3D scaffolds functionalized with 
layers of chitosan and EV-containing poly-γ-glutamic acid (γ-PGA), alternated in a layer-by-
layer system. EV entrapment in the delivery system could be confirmed by laser scanning 
confocal microscopy, using fluorescently labelled EV, but not by Fourier-transform infrared 
spectroscopy. Then, the release profile of EV from the delivery system was evaluated in vitro 
by transmission electron microscopy of release supernatants, at 0, 12 and 24 h of incubation, 
and EV could be detected in concentrated supernatants, particularly at 12 h of release. At the 
functional level, EV-loaded delivery systems produced were tested for their capacity to 
promote recruitment, and osteogenic and chondrogenic differentiation of multipotent 
mesenchymal stromal/stem cells (MSC), responsible for bone formation. Using time-lapse 
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video microscopy we showed that EV entrapped in the delivery system were able to promote 
significant MSC motility. Also, gene expression analysis results indicate that while Ch and γ-
PGA delivery systems were pro-chondrogenic, the presence of EV did not increase MSC 
differentiation further. 
In conclusion, EV could be entrapped in the layer-by-layer Ch and γ-PGA 3D systems, and 
were functional upon release. The KG-1-secreted EV used, similarly to those of primary 
Dendritic Cells, induced an MSC recruitment-promoting behaviour, increasing their motility, 
while the Ch and γ-PGA delivery system per se promoted chondrogenic differentiation. 
Together, our results support a beneficial effect of EV entrapment and controlled release, 
upon MSC, suggesting EV as chemoattractants for this cell type into places of bone injury, 
where one can envisage the delivery system may enhance their differentiation, promoting 
tissue repair and regeneration. 
 
Key words: Bone regeneration, delivery system, extracellular vesicles, mesenchymal stem 
cells  
 
 
 
 
 
 
ix 
 
 
Agradecimentos 
 
 
 
É com grande alegria que vejo concluída mais uma etapa da minha vida. No entanto, esta 
não seria possível sem todas as pessoas que me ajudaram e estiveram presentes em todos os 
momentos, bons ou menos bons, que permitiram que o culminar desta aventura resultasse 
neste trabalho. 
Um Obrigada especial à Susana Santos, minha orientadora e sem dúvida um exemplo de 
trabalho e dedicação! Por todo o tempo e atenção dedicado para que este trabalho 
resultasse.   
Ao Professor Mário Barbosa, diretor do i3S e PI do grupo onde me integrei, obrigada por 
ser um ser Humano por detrás de um grande Cientista e partilhar connosco histórias que 
ensinam.   
A todos os membros da equipa técnica no I3S: ao Rui, por toda a boa disposição e ajuda a 
adquirir as melhores imagens no TEM; à Cecilia por toda a ajuda com o NTA; à Joana Rocha e 
Dalila por toda a ajuda e cooperação na sala de culturas.  
Um agradecimento também a toda a equipa, Microenvironments for New Therapies, que 
me integrou da melhor forma e me ajudou a crescer, não só a nível científico, mas também a 
nível pessoal. Desta equipa, não consigo deixar de falar em particular da Andreia, minha co-
orientadora e, a pessoa que me acompanhou desde o iníco e me transmitiu tanto 
conhecimento e o fez de forma tão incrível, que faltam as palavras para descrever o quão 
importante foi neste percurso. É das melhores pessoas que já conheci e que melhor concilia 
conhecimento científico com alegria e energia! Obrigada por tudo, mesmo! Ao José Henrique 
e ao João Brás por toda a boa energia e por estarem sempre prontos a ajudar. À Joana 
Magalhães por ser a melhor companheira de secretária e por ter sempre uma palavra de força 
para todas as situações. À Catarina Leite por toda a ajuda, em especial com o PGA. Obrigada 
por terem tornado este percurso mais fácil e tão agradável de se fazer.  
Não podia deixar de falar daqueles que me acompanham desde sempre e nunca recusam 
uma cerveja no Inox para aliviar o stress de uma semana de trabalho: um enorme obrigada à 
Anita e ao Samuel por todo o companheirismo e amizade. Ao Fábio, à Inês, ao Adão e à 
Kristine por todas as pausas culturais ou não, mas necessárias. Um obrigada especial à minha 
amiga de casa, Márcia, foi um prazer partilhar contigo esta jornada que vai deixar saudades. 
À Marisa, por nunca dizer que não a um jantar e por todas as idas ao ginásio para recarregar 
 x 
 
baterias! Ao João Sousa e à Ana Gomes, por, mesmo menos perto, continuarem sempre 
presentes! À Bárbara, por todo o apoio e amizade! Ao Rodrigo por, mesmo longe, me 
conseguir ajudar a traçar os meus objetivos e por ter sempre alguma coisa a acrescentar. Ao 
Francisco Teixeira por toda a amizade e atenção. Ao Francisco Branco por toda a força e 
exemplo de ambição e coragem. Aos amigos de Carlão, que me viram crescer e que sempre 
acreditaram em mim. Sou uma sortuda por vos ter na minha vida! 
À minha família, por tudo o que sou hoje. Ao meu pai por todos os fim-de-semana querer 
saber qual é o tema da minha tese e por tudo que me ensinou e continua a ensinar. À minha 
mãe, por me apoiar na sobrevivência das células em cultura, e por todas as marmitas feitas 
com tanto carinho. Ao meu irmão por ser o miúdo mais incrível que conheço e por contar os 
dias para eu voltar a casa. À minha irmã, por, mesmo longe, me apoiar em tudo e por ser um 
exemplo para mim!  
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial support 
This work was financially supported by: Project no. S-15-83S, from AO Foundation 
(Switzerland); project NORTE-01-0145-FEDER-000012, supported by Norte Portugal Regional 
Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, 
through the European Regional Development Fund (ERDF); Portuguese funds through FCT - 
Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Inovação, in the 
framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-
0145-FEDER-007274) 
 
 
 
xi 
 
 
Table of Contents 
 
 
 
Chapter 1 ................................................................................. 1 
Introduction .................................................................................................................... 1 
1.1 – Cell- secreted extracellular vesicles ............................................................................. 2 
1.1.1 - Extracellular vesicles: characteristics and methods of isolation.......................................... 2 
1.1.2 - EV characterization: methods of analysis ............................................................................ 5 
1.1.3 - Therapeutic potential of EV ................................................................................................. 7 
1.2 – Strategies for EV delivery ........................................................................................... 10 
1.2.1 – Systemic delivery of EV ..................................................................................................... 10 
1.2.1.1 - EV intravenous administration ....................................................................................... 10 
1.2.1.2 - EV intraperitoneal administration .................................................................................. 12 
1.2.1.3 - EV oral administration .................................................................................................... 12 
1.2.1.4. EV intranasal administration ........................................................................................... 13 
1.2.2 - Local delivery of EV ............................................................................................................ 14 
1.3 – Delivery Systems: from Drug to EV Delivery .............................................................. 17 
1.3.1 - Chitosan and poly-γ-glutamic acid: Biomedical Applications ............................................ 19 
1.3.2 – Chitosan as a delivery system ........................................................................................... 19 
1.3.3 – Poly-γ-glutamic acid as a delivery system ......................................................................... 22 
1.3.4 – Combining chitosan and poly-γ-glutamic acid in a layer-by-layer delivery system .......... 22 
1.4 – Objectives ................................................................................................................... 25 
Chapter 2 ............................................................................... 27 
Methods and Materials ................................................................................................. 27 
2.1 - Cell culture .................................................................................................................. 27 
2.2 – Cell viability Assays ..................................................................................................... 28 
2.3 - EV production, isolation and characterization ............................................................ 28 
2.3.1 – EV production and Isolation .............................................................................................. 28 
2.3.2 - EV characterization ............................................................................................................ 28 
2.4 – Production of EV delivery systems ............................................................................. 29 
2.4.1 – Chitosan scaffolds production .......................................................................................... 29 
2.4.2 – Poly-γ-Glutamic Acid production ...................................................................................... 29 
2.4.3 – Scaffolds functionalization with a chitosan/γ-PGA Layer-by-Layer system ...................... 30 
2.5 – Delivery system characterization ............................................................................... 31 
2.5.1 – Confocal microscopy ......................................................................................................... 31 
2.5.2 - FTIR .................................................................................................................................... 31 
2.5.3 – EV release assay ................................................................................................................ 31 
2.6 – MSC transwell recruitment assay ............................................................................... 32 
 xii 
 
2.7 – Timelapse MSC motility assay .................................................................................... 33 
2.8 – MSC differentiation assay .......................................................................................... 34 
2.9 – Statistical analysis ....................................................................................................... 36 
Chapter 3 ............................................................................... 37 
Results .......................................................................................................................... 37 
3.1 – Optimization of cell culture conditions for EV production ........................................ 37 
3.2 – Immune cell EV secretion and characterization ......................................................... 40 
3.3 – Delivery system component characterization............................................................ 43 
3.4 – Layer-by-Layer system is able to entrap EV ............................................................... 43 
3.5 – Layer-by-Layer EV release profile ............................................................................... 46 
3.6 – Effect of EV from the delivery systems in MSC migration ......................................... 47 
3.7 – Functional impact of LbL-mediated EV delivery on MSC differentiation ................... 48 
Chapter 4 ............................................................................... 51 
Discussion and future perspectives ................................................................................ 51 
References ............................................................................. 57 
Supplementary information ........................................................ 71 
Annex 1 ................................................................................. 73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
 
List of figures 
 
 
 
Figure 1.1 - Schematic representation of the sizes of the different types of extracellular 
vesicles that can be secreted by cells.. ................................................................... 3 
Figure 1.2 - Extracellular vesicles biogenesis, release, and mode of action. ...................... 4 
Figure 1.3 - Extracellular Vesicles are natural and tunable delivery vehicles with clinical 
potential in tissue repair and regeneration. .............................................................. 7 
Figure 1.4 - Routes of administration of Extracellular Vesicles. ................................... 10 
Figure 2.1 - Scheme of synthesis of the LbL system on Ch scaffolds. ............................. 31 
Figure 2.2 - Transwell migration assay setup to test MSC migration in the presence of 
different stimuli.............................................................................................. 33 
Figure 2.3 - Schematic representation of the system used for MSC motility assay in the 
presence of different stimuli. ............................................................................. 34 
Figure 2.4. Schematic representation of the transwell system used to test MSC differentiation 
in the presence of different stimuli.. .................................................................... 35 
Figure 3.1 – Morphology in culture of all tested cell lines.. ......................................... 38 
Figure 3.2 - Characterization of cell viability of the three cell lines tested, when cultured in 
different serum conditions. ................................................................................ 39 
Figure 3.3 – Characterization of EV from KG-1, THP-1 and Jurkat cell lines. .................... 41 
Figure 3.4. Characterization of EV isolated from KG-1 cells. ....................................... 42 
Figure 3.5. (A) B.subtilis culture in Agar. (B) SDS-PAGE to determine the Mw of γ-PGA 
produced. ..................................................................................................... 43 
Figure 3.6 - Layer-by-layer system with entrapped EV. ............................................. 44 
Figure 3.7 - FTIR spectra of EV-containing LbL systems. ............................................ 45 
Figure 3.8 - EV release from LbL systems. ............................................................. 46 
 xiv 
 
Figure 3.9 – MSC recruitment in a transwell migration assay, as influenced by different 
stimuli. ........................................................................................................ 47 
Figure 3.10 - MSC migration profile in time-lapse motility assays. ................................ 48 
Figure 3.11 – Osteogenic and chondrogenic differentiation of MSC in the presence of LbL with 
and without EV. .............................................................................................. 49 
Figure S1 - Overview of all cutting steps of chitosan scaffolds until the desired size is 
achieved. ...................................................................................................... 71 
Figure S2 – Representative gel image of RNA extracted analyzed by agarose gel 
electrophoresis. .............................................................................................. 71 
Figure S3 – Representative gel image of RT-qPCR products analyzed by agarose gel 
electrophoresis for RUNX2 in MSC stimulated with osteogenesis-inducing media (Osteo), SOX9 
in MSC stimulated with chondrogenesis-inducing media (Chondro) and for GAPDH, RUNX2 and 
SOX9 in MSC stimulated with the LbL delivery system with entrapped EV (from left to right, 
respectively). ................................................................................................. 72 
Figure S4 - Scanning electron microscopy analysis of scaffolds with entrapped EV, as 
previously performed in the lab. .......................................................................... 72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xv 
 
 
List of tables 
 
 
 
Table 2.1 - Sequence of the primers used in the RT-qPCR analysis performed on MSC, for the 
genes RUNX2, SOX9 and GAPDH. .......................................................................... 35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xvi 
 
 
 
 
 
 
 
 
 
xvii 
 
 
Abbreviations 
 
 
 
AFM   Atomic force microscopy 
ATR-FTIR  Attenuated total reflection-Fourier-transform infrared spectroscopy 
BBB   Blood brain barrier 
BC   Bottom compartment 
bFGF   Basic Fibroblast Growth Factor 
CCl4   Carbon tetrachloride 
cDNA   Complementary DNA 
CFSE   5-carboxyfluorescein diacetate succinimidyl ester 
Ch   Chitosan 
Cx43   Connexin 43 
DAPI   4′,6-diamidino-2-phenylindole 
DC   Dendritic cells 
DDS   Drug delivery system 
DLS   Dynamic light scattering 
DNA   Deoxyribonucleic acid 
DTH   Delayed-type hypersensitivity 
ER   Endoplasmic reticulum 
EV     Extracellular vesicle  
FBS   Fetal bovine serum 
FasL   Fas ligand 
FDA   Food and Drug Administration 
FTIR   Fourier-transform infrared spectroscopy 
γ-PGA   Poly-gamma-glutamic acid 
GM-CSF   Granulocyte-macrophage colony-stimulating factor 
IL   Interleukin 
iPS   Induced pluripotent stem cell  
i.v.   Intravenous injection 
IFN-γ   Interferon- γ 
LB   Luria Broth media 
LbL   Layer-by-layer 
LSCM   Laser scanning confocal microscopy 
MCP-1  Monocyte chemoattractant protein 1  
miRNA(s)              MicroRNA(s) 
MSC   Multipotent mesenchymal stromal/stem cell 
 xviii 
 
MV   Microvesicles 
MVB   Multivesicular bodies 
Mw   Molecular weight 
MWCO   Molecular weight cutoff 
NTA   Nanoparticle Tracking Analysis 
PBS   Phosphate-buffered saline 
PI   Propidium iodide 
PGA   Poly-glutamic acid 
PLGA   Poly(D,L-lactide-co-glycolide) 
P/S   Penicillin/streptomycin 
rhBMP-2  Recombinant human bone morphogenetic protein-2 
RNA   Ribonucleic acid 
Rluc   Renila luciferase 
RS   Raman spectroscopy 
RT   Room temperature 
RVG   Rabies virus glycoprotein 
RT-qPCR  Quantitative real time polymerase chain reaction 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
siRNA   Small interfering RNA 
SFM   Serum-free media 
SMSC   Synovium mesenchymal stem cells 
SPR   Surface plasmon resonance 
SN   Ultracentrifugation supernatant 
TC   Top compartment 
TEM   Transmission electron microscopy 
TPP   Tripolyphosphate 
tRPS   Tunable resistive pulse sensing 
UC   Ultracentrifuged 
 
 
 
1 
  
 
 
 
Chapter 1 
 
 
This chapter was adapted into a manuscript that was submitted for publication, and that 
is included as an annex (Annex 1) to this thesis. 
Alice Pinheiro, Andreia M. Silva, José H. Teixeira, Raquel M. Gonçalves, Maria I. Almeida, 
Mário A. Barbosa, Susana G. Santos. Extracellular Vesicles: Intelligent delivery strategies 
for therapeutic applications. (submitted) 
 
Introduction 
 
 
 
The response to tissue injury requires well-orchestrated communication between the cells 
responsible for its different stages, from the initial inflammation to repair/regeneration. In 
the last decades, the roles of Extracellular Vesicles (EV), secreted by cells, in these processes 
have been the subject of intense research [1]. Three different types of EV secreted by cells 
have been reported and characterized, based on their origin, release mechanism and 
properties: apoptotic bodies, microvesicles and exosomes. Although the complete distinction 
of these different vesicle populations is still hindered by methodological limitations, the last 
two types of vesicles have deserved most attention from the scientific community, due to 
their biological properties [2]. Nonetheless, due to the persisting difficulties in fully 
distinguishing these vesicle populations, and in agreement with the recommendations of the 
International Society of Extracellular Vesicles, in this thesis the designation EV will be 
preferentially used. 
The most intensely studied EV population is that of exosomes, nanometre-sized vesicles 
formed in the endosomal network and secreted by the majority of cells, including tumor cells 
[3] [4]. Exosomes are reported to play key roles in intercellular communication, without cell-
to-cell contact. They have been reported to participate in different homeostatic biological 
processes, including antigen presentation, delivery of active biomolecules to target cells, and 
even cell waste management (initially thought to be their only function) [5]. These natural 
functions of exosomes have been explored for their application as therapeutic mediators in 
different fields, from cancer treatment to novel tissue regeneration strategies. However, 
they may also contribute for the spreading of infecting pathogens and pathologies, namely 
cancer metastasis [6].  
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EV have also been greatly explored as biomarkers of disease, because their composition is 
related to the status of the cell from which they derive. Recent studies have shown that the 
characterization of exosomes in fluids, particularly in the blood, urine, saliva, breast milk and 
amniotic fluid can strongly contribute for the diagnosis of various diseases, namely in cancer 
[7] [8]. This makes the use of EV as biomarkers to be applied in areas such as diagnosis, 
prognosis, as well as real-time monitoring of therapy of different pathologies by determining 
their levels and composition in body fluids [7] [9] [10].  
On the other hand, EV can be obtained in vitro from different cells, and are reported to 
be stable when administered in vivo, which are important advantages for their application as 
a drug, or as drug delivery system. In addition, they can be obtained from the patient own 
cells, an important advantage regarding their immune compatibility [11]. Indeed, considering 
their clinical value, EV have been increasingly investigated in the delivery systems field. Many 
studies have been reporting their use to deliver different molecules such microRNAs 
(miRNAs), siRNAs, proteins or drugs to target cells [2]. However, despite the increasing 
research in EV field, there are several difficulties in their isolation and characterization 
process. Many isolation procedures have been described but in all of them, a very low EV 
yield is reached. In addition, there is a lack of characterization methods able to efficiently 
evaluate EV standardized production from different cell culture batches. Both issues 
constitute a big obstacle to make EV clinical applications succeed. On the other hand, when 
administered in vivo, exosomes are readily cleared form circulation. Furthermore, the 
mechanisms controlling the specific delivery of exosomes to a specific target are fairly 
unknown and need to be studied harder. These limitations are the main motivations 
underlying this master thesis. Thus, they will be further addressed in the following sections, 
along with possible strategies to overcome them.  
 
1.1 – Cell-secreted extracellular vesicles 
 
1.1.1 - Extracellular vesicles: characteristics and methods of isolation 
Most cells are capable of releasing different types of EV, which are generally divided in 
three classes: exosomes, microvesicles, and apoptotic bodies. Each type of EV can be 
classified based on different criteria, such as origin in the cell, size, and enrichment of 
specific protein markers. Figure 1.1 establishes a close relationship between the sizes of the 
three different vesicles. However, this classification is still controversial with different 
authors reporting different sizes for the same EV population. 
 
 
 
 
 
1.1 – Cell-secreted extracellular vesicles  3 
 
 
 
 
Figure 1.1 - Schematic representation of the sizes of the different types of extracellular vesicles that 
can be secreted by cells. Exosomes may range from 50 to 150 nm (are the smallest). Next, microvesicles 
can range from 50 nm to 1 μm. The largest vesicles are the apoptotic bodies and can reach 5 μm. 
Adapted from [12]. 
 
The microvesicles originate by direct budding from the plasma membrane and their size is 
quite variable (50 nm - 1 μm) [13]. As for the apoptotic bodies, they are released when the 
cell is undergoing apoptosis [14], and are an even more heterogeneous population, ranging in 
size from 50 nm to 5 μm [10]. On the other hand, exosomes are characterized by being the 
smallest EV, with sizes in the range of 50-150 nm, being derived from the intraluminal bud of 
multivesicular bodies (MVB), and that are released after fusion of these MVB with the plasma 
membrane (shown in Figure 1.2) [10]. As a common feature among them, all types of EV are 
lipidic vesicles that carry a protein content in their core, as well as on their surface. They 
also carry different types of RNAs, including messenger RNA and miRNAs, DNA, and even 
different metabolites. Importantly, these biomolecules are functional, even when delivered 
to target cells. There are three main mechanisms by which EV interact with target/recipient 
cells: endocytosis; direct fusion with the plasma membrane of the recipient cell; and 
receptor-mediated endocytosis following receptor–ligand interaction between EV and the 
recipient cell [15]. 
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Figure 1.2 - Extracellular vesicles biogenesis, release, and mode of action. Cells secrete different types 
of extracellular vesicles, including microvesicles (MV), exosomes and apoptotic bodies. Apoptotic bodies 
are formed during programmed cell death. MV are released by cell membrane budding of, whereas 
exosomes have their origin in multivesicular bodies (MVB). Upon release, EV travel body fluids until they 
reach a target cell. Since EV carry biomolecules such as proteins, messenger RNA, microRNA (miRNA) 
and DNA, they are able to modulate the phenotype of target cells. Adapted from [16].   
  
Upon secretion, these different EV are present together in body fluids or supernatants of 
in vitro cell cultures, and separation methodologies are required to allow the study of each 
EV population. Different methods have been developed and optimized in the last years to 
isolate these EV populations, particularly exosomes, with different degrees of efficiency. 
These methods include differential centrifugation with a final step of ultracentrifugation, or 
ultracentrifugation in density gradients, phase separation, size-exclusion chromatography, 
immunoprecipitation and filtration. Differential (ultra)centrifugation is still the method most 
commonly reported for the isolation of EV, although EV pellets obtained are generally a mix 
of exosomes, microvesicles and soluble proteins secreted by cells, since many proteins have 
sedimentation coefficients similar to EV [14]. In order to isolate pure EV populations, soluble 
protein aggregates, denser than EV, may be removed by ultracentrifugation using sucrose 
cushions or gradients [14] [17]. 
Size-exclusion chromatography also allows the separation of EV from contaminant soluble 
proteins. Importantly, it is perhaps one of the most complete methods for the separation of 
different EV populations, since apoptotic bodies, microvesicles and exosomes are eluted in 
different fractions of the eluate [18]. Due to their easy implementation, exosome isolation by 
phase separation is becoming increasingly popular, being available in commercial kits 
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nowadays. However, a major drawback of this method is the common precipitation of 
microvesicles and soluble proteins alongside exosomes [19].  
Up to date, centrifugation in density gradients and size-exclusion chromatography are the 
preferred techniques for the isolation of pure exosome populations [20]. However, the yield 
of isolation is usually very low and the isolation protocols are time-consuming, impairing a 
wider use of these methods.  
Considering the difficulties in isolating pure populations of the different types of EV, it is 
of utmost importance that the vesicles isolated are extensively characterized [17]. However, 
distinguishing and quantifying the different subtypes of EV remains a difficult task because of 
several similarities in size and physical properties of the different subtypes, and the lack of 
specific markers for each one of them [14].  
 
1.1.2 - EV characterization: methods of analysis 
In order to characterize the isolated EV several techniques are usually combined. So far, 
the main techniques used are transmission electron microscopy (TEM), atomic force 
microscopy (AFM), flow cytometry, western blotting, nanoparticle tracking analysis (NTA), 
dynamic light scattering (DLS), tunable resistive pulse sensing (tRPS) and surface plasmon 
resonance (SPR). More recently, Raman spectroscopy has also been applied to the 
characterization of EV.  
A primordial technique used in the field of EV biology, and still the most used for 
determining EV morphology, and even to visualize their release from cells is transmission 
electron microscopy (TEM). This technique also allows to determine the size of individual EV 
with minimal sample processing. Biochemical information about the EV can also be obtained 
with this method, by using immunogold labelling. However, this technique has limitations 
related to preparation of the sample, since it must be dehydrated and analysed under vacuum 
[21]. The AFM is also used for the characterization of EV, however, few studies follow this 
approach, due to the need of immobilization of the vesicles under study. Moreover, the most 
suitable EV immobilization method, that could retain the physiological properties of the 
vesicles, is still being discussed. Besides retrieving information regarding vesicles size and 
morphology, AFM also allows characterizing their mechanical properties [22] and potentially 
their interactions, for instance with cells. 
For a more detailed biochemical analysis, EV are usually characterized based on the 
proteins they carry on their surface [7]. Tetraspanins (CD37, CD53, CD63, CD81 and CD9) are 
highly enriched in EV, and thus are generally accepted as EV markers. CD63 is perhaps the 
most reported EV marker [23] [24]. However, several positive and negative markers of EV 
should be tested simultaneously. The specific detection of these markers by antibodies is 
usually achieved by flow cytometry or western blotting. Flow cytometry allows simultaneous 
multi-parameter analysis on EV. However, a disadvantage of this technique is that common 
flow cytometers cannot distinguish light scatter from one single EV, and thus, their analysis 
by flow cytometry usually requires an additional step of vesicle coupling to carriers of larger 
size [21]. Multiple EV are often count as a single EV, precluding an accurate analysis of EV 
concentration and size [25]. Thus, the use of larger beads with EV absorbed, followed by 
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fluorescent antibody labelling, is still the most common solution to characterize EV by flow 
cytometry [14]. Protein markers can also be assessed by western blot, the main disadvantage 
is that the analysis is of a protein pellet, and not individual vesicles. This technique can be 
associated to immunoprecipitation, using the classical EV markers (CD9, CD63 or CD81), and 
analysing the immunoprecipitated vesicles directly by western immunoblotting for the 
detection of additional markers [26]. 
To analyse changes in the amount of EV produced in different conditions and also to 
determine EV concentration and size distribution, for analysis of the isolated populations and 
for standardization of functional assays, the most used methodologies are nanoparticle-
tracking analysis (NTA) and dynamic light scattering (DLS). NTA is the most widely used 
technique to assess EV size and concentration [21] [27]. In general, this technique gives 
information about EV size distribution and concentration in solution, and allows real-time 
virtual visualization of the vesicles [28]. In some equipment, fluorescence can be combined 
with this method, by labelling EV directly with fluorescent dyes or immunolabelling specific 
molecules with fluorescent-conjugated antibodies [21]. Concerning NTA limitations, it is 
known that instrument-specific variables affect the characterization of EV, limiting the 
analysis of very heterogeneous populations [29]. In addition, the use of fluorescently-labelled 
antibodies for the analysis of EV increases specificity, but may limit the analysis to specific 
subpopulations, as discussed by Rafal et al. [21]. Similarly to NTA, dynamic light scattering is 
a technique used for EV size characterization and EV distribution with the variance of 
scattered light intensities detected in a specific angle and then compared to the wavelength 
of light [7]. Importantly, this technique allows determining the surface charge of the vesicles, 
an important parameter for their internalization by target cells. In recent years, a few works 
were published reporting the use of tunable resistive pulse sensing (tRPS) to characterize EV 
suspensions. This technique calculates EV absolute size, their concentration in the sample and 
their surface charge [21]. These values are calculated in comparison with reference particles 
with known volume and concentration [27]. However, Maas et al. concluded that different 
operation variables could affect significantly EV quantification [27].  
Other tools are being developed to improve accuracy and detail in EV characterization. 
For instance, surface plasmon resonance (SPR) allows real-time and label-free detection of 
ligand binding to target receptors located on a sensing film [30]. Im et al. performed EV 
populations characterization by using a nanohole-based SPR sensor, being 10 000 times more 
sensitive than western blotting analysis, and allowing a fast characterization of EV [31]. In 
addition, Raman Spectroscopy (RS) analyses chemical vibrational modes of the samples due to 
wavelength shifts [32]. RS generates a spectrum with qualitative and quantitative information 
to describe chemical composition of EV. With this, the use of specific protein biomarkers is 
not required. Unlike all the previously described techniques, RS provides label-free 
determination of chemical composition of even a single EV in a short time [33]. Due to these 
advantages, this technique is being increasingly investigated as a fundamental analytical tool 
in EV characterization field [34].  
Despite all the technical advances achieved in the last years, basic EV characterization 
techniques are far from being used in diagnostics. In addition, they are still very limited for 
the characterization of EV to be administered in in vivo models, and to quantify their 
distribution in the body upon administration. The important role of EV, in particular as 
potential therapeutic tools, makes it necessary to further improve the techniques of 
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quantification and characterization of these vesicles. To reach clinical practice, a fast sample 
characterization, based on a fingerprint characterization of EV populations, must be 
achieved, and improved experimental settings and routines of analysis must be implemented 
[27] [35].  
 
1.1.3 - Therapeutic potential of EV 
It is nowadays recognized that EV play important roles in intercellular communication, 
which renders them a natural mechanism for transferring information between cells. In 
particular taking advantage of their nanosize, EV are being explored as nanodevices for 
therapeutic applications [36]. Our group recently reviewed the potential contributions of EV 
to the different stages of tissue repair and regeneration, as illustrated in Figure 1.3. 
 
 
Figure 1.3 - Extracellular Vesicles are natural and tunable delivery vehicles with clinical potential in 
tissue repair and regeneration. EV are produced by virtually all cell types in the body and their content 
varies with physiological conditions, playing crucial roles during the inflammatory, remodelling and 
repair stages of tissue regeneration. Furthermore, natural EV can be modified to carry miRNAs, mRNAs, 
proteins and drugs of interest, functioning as improved therapeutic vehicles. Adapted from [37]. 
 
Naturally, EV carry active biomolecules that are loaded into their core or incorporated in 
their membrane through cell endogenous mechanisms [10] [38] [39]. The content of EV 
constitutively secreted by a cell reflects its physiological condition, and will impact on their 
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effect on target cells. Different roles have been described for EV, that may contribute to the 
different stages of tissue repair/regeneration. For instance, researchers previously showed 
that the RNA cargo of MSC-derived EV is different according to the MSC tissue source [40]. 
Also, EV secreted by immune cells in different stages of activation may elicit either 
immunostimulatory or immunosuppressive responses on target cells [41]. In addition, EV have 
been described for many years as having a role in bone matrix mineralization [42]. 
In order to improve the therapeutic potential and to standardize the effects of EV, the 
investigation into modified and artificial EV has been increasing. Much like with synthetic 
nanoparticles, different types of molecules such miRNAs, messenger RNAs, siRNAs, proteins, 
and even drugs, can be specifically incorporated into EV, which become the transporters of 
these molecules to target cells [43]. EV may be loaded with different molecules either 
exogenously or endogenously. In the first approach, the molecule of interest is included into 
EV after their isolation and purification, while the endogenous approach is based on active 
encapsulation during EV biogenesis, via transforming the EV-producing cells with the selected 
molecule [43].   
EV have been most explored in the cancer field, where their potential roles and 
applications are more intensely researched. Their use in immunomodulatory therapies or 
directly anti-tumor therapies has been recently reviewed [17]. Recently, the anti-tumor 
therapies based on anti-cancer drug loading on EV have been the most studied. Saari et al. 
studied the cytotoxic effect of EV isolated from prostate cancer lines cultures, and loaded 
with the antimitotic cancer drug Paclitaxel, upon the same type of cancer cell [44]. They 
showed that loaded EV decreased cell viability, and generated better cytotoxic effects than 
the free drug, which was mediated by EV internalization by cancer cells. Also, using EV 
loaded with high dosage of Paclitaxel, Pascucci et al. showed great results in vitro in 
pancreatic cancer therapy [45]. This study introduced the ability of EV secreted by MSCs, 
which were previously loaded with Paclitaxel, to incorporate the drug during vesicle 
biogenesis. Interestingly, these EV retained anti-tumor activity in vitro. Many other studies 
reported the use of chemotherapeutics loaded in EV, supporting their use as drug vehicles as 
a good alternative to traditional cancer therapy. This is mainly due to a great reduction in 
toxic side effects, since EV biodistribution to target tissues may be increased by choosing 
appropriate parental cells for EV production [46] [47]. However, many different ways to 
further enhance effects and tailored targeting of these EV are being tested, so that EV 
therapies become a reality in clinical applications.  
EV have also been studied for the development of novel therapies for neurodegenerative 
disorders, which affect increasing proportions of the world population.  Haney et al. took 
advantage of the ability of EV to cross the blood-brain barrier (BBB) and incorporated catalase 
in the vesicles using different methods, in order to restore the reduced levels of redox 
enzymes, commonly observed in the brains of Parkinson’s patients. A significant amount of 
catalase-loaded EV was detected in the brain of mice tested after intranasal administration, 
particularly in their neurons and microglial cells, which resulted in a neuroprotective effect 
[48]. Similarly, EV were suggested as therapeutic vehicles in Alzheimer's disease. Alvarez-
Erviti et al. have shown the ability of engineered EV (from self-derived dendritic cells, DC), 
loaded with siRNA against BACE1 protein, to cross the BBB in mice, working as a treatment for 
Alzheimer's disease. Importantly, these EV were injected intravenously but non-specific 
effects in other tissues were not detected [49]. This work, along with other studies in the 
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field, is very promising for the EV-based treatment of different neurodegenerative diseases. 
However, some issues need to be overcome to achieve clinical trials. For example, the fact of 
the RVG peptide is exogenously expressed in EV surface in many studies targeting the brain, 
and the fact that the receptor for this peptide is often downregulated in Alzheimer’s disease 
brains, makes this practice unable to proceed to the next investigation step before further in 
vivo studies [50].  
Although cancer and neurodegenerative disorders are the fields where EV research is most 
intense, using EV as delivery systems in other areas, such as tissue repair and regeneration, 
has also gained increasing attention, particularly in models of hepatic failure, renal and 
myocardial injury. Interestingly, Wang and colleagues used EV derived from human umbilical 
cord-derived MSCs to study their capacity in preventive prophylaxis of acute graft-versus-host 
disease, in a mouse model of allogeneic hematopoietic stem cell transplantation. EV were 
intravenously administrated, and results demonstrated a decrease in in vivo manifestations of 
acute graft-versus-host disease along with decrease of mortality [51]. 
In the field of tissue repair, EV secreted by MSC have been the most studied for their 
regenerative capacity. Many studies have been demonstrating their positive effects on the 
recovery of homeostasis, as well as on the regeneration and repair of damaged tissues. This 
suggests a therapeutic effect of MSC-derived EV that can be used as an aid to various 
therapies [52] [53].  
Different injury models have been used to test the potential of MSC-derived EV as 
therapeutics. For instance, Li et al. studied the effect of EV derived from umbilical cord-MSCs 
in a carbon tetrachloride (CCl4)-induced mouse liver fibrosis. This treatment inhibited hepatic 
lobule destruction, hepatocyte apoptosis and epithelial-to-mesenchymal transition, and 
ameliorated fibrosis [54]. Many other studies used EV of different origin as delivery systems 
for the treatment of the same model of CCl4-induced liver fibrosis in mouse, reporting an 
amelioration of the condition [4] [55] [56]. Using a renal injury model, Gatti et al. 
demonstrated significant effects in reduction of epithelial tubular cell damage in an ischemia 
rat model, by using MSC-derived EV [57]. However, this knowledge has not yet been 
translated to human clinical trials [58]. EV derived from MSC were also shown to reduce 
infarct size in a mouse model of myocardial ischemia/reperfusion injury [59]. In a similar 
approach, Ibrahim et al. used EV from human cardiosphere-derived cells in a chronic 
myocardial infarction murine model. Exosome administration inhibited apoptosis of 
cardiomyocytes and interestingly, promoted their proliferation, helped by an increase of 
angiogenesis [60]. The regenerative effects of EV from MSCs were also reported in models 
with osteochondral defects [40]. In the study from Zhang et al., MSC-derived EV were intra-
articular administrated in an osteochondral defect created on distal femurs of adult rats. 
After 12 weeks, a full reparative response of the femurs was observed in rats exosome-
treated. In addition, only fibrous repair tissues were found in the control rats, PBS-treated. 
This was the first study reported the positive effects of EV derived from MSC in cartilage 
repair [61].  
In our group, we have been focusing on the crosstalk between immune cells and MSC, 
particularly on the way immune cells can influence MSC behaviour. Our previous work showed 
that DC are able to recruit MSC [62], and that DC-secreted EV are main effectors of DC-
mediated recruitment [63].  
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In the different studies published so far exploring the therapeutic potential of EV in vivo 
and in clinical trials, the strategy for vesicle administration is highly variable, using different 
routes and in different dosages. Furthermore, several EV-based therapies have been 
promoted for commercialization by several companies, for which EV dose, administration 
route, and timeplan of administration are still undisclosed and not well defined [64]. 
 
1.2 – Strategies for EV delivery 
1.2.1 – Systemic delivery of EV 
To reach the target tissue or organ, EV can be administered via different routes, such as 
intravenous, intraperitoneal, oral, intranasal, and subcutaneous (Figure 1.4), that may lead to 
their systemic distribution. 
 
Figure 1.4 - Routes of administration of Extracellular Vesicles. EV may be used in vivo as a drug. They 
can be administered either as free vesicle suspensions or loaded in drug delivery systems that allow 
their controlled release along time. Depending on the clinical application intended, they can be 
administered in different body locations, which will affect their time of retention in circulation and in 
target organs, as well as their body biodistribution.    
 
1.2.1.1 - EV intravenous administration 
The most widely used strategy for EV in vivo delivery is the intravenous injection (i.v.), 
considered the fastest way to deliver drugs and also EV, due to their direct delivery to
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 systemic circulation. In one of the earliest studies dedicated to determine EV 
biodistribution, reporter EV derived from HEK 293T cells were injected subcutaneously in 
athymic mice and their biodistribution followed by in vivo imaging [65]. These EV were 
coupled to Gaussia luciferase and biotin, allowing conjugation with labeled streptavidin for 
non-invasive in vivo fluorescence imaging, and also analysis of EV distribution by 
bioluminescence, including in biofluids such as blood and urine, upon the addition of 
luciferase substrate. As early as 30 min after administration, EV could be detected in liver 
and spleen of mice, being detected in low amounts in the brain, heart and muscle at all 
timepoints analyzed. In accordance, EV were detected at the highest concentration in blood 
at 30 min after administration, peaking in the urine at 60 min post-injection [65]. In a later 
work, Manca et al. tested the biodistribution of fluorophore-labeled milk-derived EV upon i.v. 
and oral administration. After 24h, EV administered i.v. accumulated in liver and spleen, 
while those administered by oral route accumulated only in small intestine [66]. The i.v. 
route has been used in the majority of the in vivo studies investigating EV as new anti-cancer 
therapies. For instance, i.v.-injected EV were already demonstrated to work as potent 
vaccines for induction of antitumor immunity, in the mouse [67]. In one of the first studies 
performing EV administration i.v., EV ameliorated functional recovery in a mouse model of 
acute kidney injury [68]. Several other studies performing systemic i.v. injection have been 
successful in ameliorating different brain conditions, implicating that EV in circulation are 
capable of crossing the BBB [69] [70]. Indeed, in one of the first studies using siRNA-loaded 
EV, discussed above, EV injected intravenously, could reach the mouse brain, resulting in 
specific gene knockdown [49]. In further studies, MSC-derived EV injected in the tail vein 
were capable of improving animal functional recovery in traumatic brain injury [71] and 
cerebrovascular accident [72]. This capacity of EV to readily reach the brain is a great 
advantage comparing to most of the synthetic delivery systems under development, that 
usually need to be functionalized in order to improve their penetrance across the BBB. The 
i.v. administration of EV has also been explored in the cardiovascular field, using vesicles of 
different cellular origin. In the study by Vandergriff et al. the authors show that EV isolated 
from cardiosphere stem cells cultures, when injected in the tail vain of mice with induced 
dilated cardiomyopathy, promoted heart function recovery by reducing apoptosis and fibrosis 
[73]. Furthermore, i.v. administration of EV derived from MSC were shown to reduce infarct 
size in a mouse model of myocardial ischemia/reperfusion injury [59]. The systemic 
administration of EV was also previously shown to improve local cutaneous wound healing. 
The recent work from Wang and colleagues suggested that EV derived from human adipose 
MSC decreased the size of incisional dorsal wounds in mice, upon intravenous injection [74]. 
Intravenous administration allows, with a minimally invasive procedure, that EV reach 
their target anywhere in the body, even locations distant from the place of injection, like 
internal organs. However, the short half-life index of EV in circulation after injection is one of 
the major limitations of this route of administration [75]. Indeed, as demonstrated by several 
in vivo studies, EV are readily cleared from circulation, with some works reporting a 
calculated half-life close to only 2 minutes [75]. Most commonly, EV are cleared to liver and 
lungs [75]. In a detailed study by Morishita et al., EV from B16BL6 melanoma cells were 
radioactively labeled and injected intravenously. By collecting blood and organs at different 
timepoints, and measuring radioactivity, the authors showed that, 30 min after injection, 
only 1 % of injected EV were still in blood. At the same timepoint, almost 40 % of the injected 
dose could be detected in the liver, and 10 % in the lungs, a distribution pattern that was 
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specific for those vesicles [76]. In a follow-up study, the same group indicated that the rapid 
clearance of EV from circulation after i.v. injection was mainly driven by macrophages, 
reason why the injected EV usually accumulate in the liver [77]. 
Although EV have a certain degree of specific tissue targeting, which is usually considered 
better than synthetic nanoparticles [78] [79], it is important to understand that EV clearance 
from circulation into different off-target organs might be an important drawback, for instance 
if vesicles are being used for the delivery of cytotoxic drugs. Furthermore, it is necessary to 
take into account that there are consequences of maladministration, which may be 
irreversible [10]. Indeed, serious consequences may occur when over-dosing EV is reached. 
For instance, Smith et al. reported a mouse died by asphyxiation with accumulation of EV in 
lungs, despite all the positive effects reported in regeneration of many organs [80].  
 
1.2.1.2 - EV intraperitoneal administration 
Another common method of EV administration is via the intraperitoneal route. Studies like 
the one by Liu et al. performed intraperitoneal administration of EV to modulate the immune 
response to a vein graft performed distantly, in the carotid of mice [81]. In this work, EV 
isolated from cultures of adipose tissue-derived MSC, and labeled with the PKH26 dye, were 
administered intraperitoneally and could be found after 30 min in the aortic endothelium, 
supporting the systemic distribution of the EV administered by this route. More interestingly, 
mice groups receiving the EV showed thinner neointima in the grafted carotid, which was 
correlated with a decreased macrophage infiltration and decreased expression of IL-6 and 
MCP-1 in the graft [82]. Of note, the intraperitoneal administration route allow the loading of 
larger EV doses, which may represent an advantage compared to other routes of systemic 
administration [3]. However, injected EV are also rapidly diluted to unwanted sites due to the 
big area of the peritoneal cavity [83]. 
 
1.2.1.3 - EV oral administration 
Oral administration is the most convenient route for pharmaceutical products intake, due 
to ease of administration, facilitating patients’ compliance to treatment. However, in this 
route EV face important obstacles. The intestinal barrier, changes in pH along the 
gastrointestinal tract and the characteristics of the intestinal microflora are further aspects 
that EV need to overcome to reach their target tissue or organ. Rezaie et al. suggested that 
this type of administration is mostly successful for delivery in luminal epithelial surface of the 
gastrointestinal tissues than in other target tissues [83]. Comparatively to other routes of 
administration, few studies were published so far reporting EV administration by oral route. 
Moreover, the works published mainly report the administration of milk-derived EV. In 2015, 
Arntz et al. reported the first oral delivery of bovine milk-derived EV with effects in arthritis 
[84]. Researchers used two different mouse models of arthritis and tested the capacity of 
these EV to delay the appearance of the disease and the evolution of the inflammatory 
phenotype. After EV administration, by oral gavage or in drinking water, histology analysis 
confirmed the delay of the arthritis as well as a decrease of cartilage and bone marrow 
inflammation. Serum levels of pro-inflammatory cytokines were also reduced [84]. Agrawal et 
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al. used EV from bovine milk for oral delivery of the chemotherapeutic drug Paclitaxel. To 
demonstrate the therapeutic effect of these vesicles, they used a female athymic nude mice 
model with lung tumor xenografts. Results showed a higher effect of drug-loaded EV on the 
inhibition of tumor growth, compared to control groups treated with PBS, the free drug or EV 
alone. Importantly, they observed a reduced systemic toxicity and inflammation when loaded 
EV were administered orally, comparing to their intravenous administration [85]. Thus, from 
this study, oral administration appears as a good alternative to decrease toxic side effects of 
EV systemic administration and to make EV-based therapies more efficient. The same group 
reported similar observations for milk EV loaded with the anti-cancer drug curcumin [86]. 
Upon oral administration of these loaded EV in mice bearing cervical tumor xenografts, 
tumors had lower volumes compared to control animals. However, curcumin could be found in 
lungs, liver and brain, in a dose dependent on EV dose administered [86].  
 
1.2.1.4. EV intranasal administration 
The intranasal route is also used for EV administration, with the first studies reporting this 
approach for the induction of a systemic immune response against air-borne pathogens  using 
EV from infected macrophages [87], and to promote tolerogenic immune responses to air-
borne allergens using bronchoalveolar lavage fluid-derived EV [88]. However, this route is also 
particularly interesting for the delivery of pharmaceutical products to the brain, either by 
entering the nearby circulation followed by crossing of the BBB, or directly through olfactory 
and trigeminal nerve cells [89]. Moreover, EV passage to circulation via the nasal route 
diminishes EV loss, because it avoids the intestinal and hepatic metabolism [90]. Indeed, this 
kind of administration showed great results in studies for Parkinson’s disease therapy in 
mouse models of this condition, having neuroprotective effects [48]. Furthermore, the EV 
intranasal administration was reported to be more effective in retaining the vesicles in brain 
tissue than their systemic administration via intravenous injection in the tail vein [91].  
Comparing different routes of administration, Yan et al. used EV from human umbilical 
cord MSCs in a murine model of hepatic oxidant injury, the CCl4-induced acute liver failure. 
EV administration was tested orally and by injection in the tail vein, with different doses 
being tested. Both investigated routes showed similar effects, which gives advantage to the 
oral route due to the ease of administration. The results demonstrated significant antioxidant 
effects in CCl4- and H2O2-injured cells. In addition, cell viability increased after EV 
administration. However, the mechanism underlying EV effect in hepatic oxidative stress 
remained unclear [92]. 
It is important to note that the classification of systemic and local routes of 
administration is not entirely linear. There are routes of administration, like the 
intraperitoneal, the intranasal or the subcutaneous, that are most commonly considered 
routes of local delivery. However, they can also be considered routes of systemic delivery, 
depending on the situation. In the case of subcutaneous injection, it can be used for local 
administration or be considered systemic administration (as detailed in the next section), 
when intended to act far from the site of administration, achieving systemic circulation. 
Intraperitoneal administration is considered systemic, but in fact it is mainly used to reach 
the gut, without necessarily going through the systemic circulation. Also, intranasal 
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administration can be used to reach the systemic circulation, but it is mainly exploited for its 
proximity to the brain. 
Altogether, the different routes of systemic administration have some common 
limitations. The distance and barriers that EV have to travel until reaching their target cells, 
implies that most vesicles do not reach the target, and instead accumulate in other organs. 
Common constraints influencing EV biodistribution include passage through physical barriers 
such as capillary endothelium, gastrointestinal epithelium and the BBB, uptake by non-target 
tissues, including entrapment in their extracellular matrix, phagocytosis by immune cells, 
particularly macrophages, and clearance in urine. Ultimately, this implies that higher EV 
doses have to be administered in order to achieve the intended biological effect at the target 
tissue. One possible strategy to overcome these problems is to increase EV tropism to the 
tissue of interest. This may be achieved by EV functionalization with surface proteins binding 
ligands on target tissues. In fact, Tominaga and colleagues demonstrated that the 
transfection of surface proteins from donor cells in EV-producing cells functioned as strategy 
to harness EV with special tropism to the brain [93]. Thus, it remains a challenge in the EV 
delivery field to find the responsible proteins for different targets, in order to achieve natural 
organ tropism for EV. Another possible strategy to increase the chance of EV reaching their 
target tissue is their modification with “don’t eat me” signals, such as CD47, which allows 
escaping the engulfment by immune cells [94]. Alternatively, to minimize the adverse effects 
of EV systemic administration, they can also be delivery directly to the target tissue. 
 
1.2.2 - Local delivery of EV 
Local drug administration is generally associated with reduced side effects [10], which 
will likely be the case also for EV. Furthermore, local administration of EV may overcome the 
often-reported low retention rates of the vesicles at specific target sites, compared to non-
specific organs. 
One of the first studies reporting the local effect of EV dates back over a decade, to 2006, 
when Kim et al. demonstrated that EV derived from genetically modified murine bone marrow 
DC (overexpressing FasL), when administered locally, could resolve inflammation in a murine 
model of delayed-type hypersensitivity (DTH), and suppress the signals of arthritis in a 
collagen-induced arthritis mouse model. They administered EV via local injection in the 
footpad and via systemic intravenous injection, and concluded that both were effective in 
suppression of the DTH response and in the treatment of collagen-induced arthritis. However, 
EV injected locally were not detected in the animals liver or spleen, suggesting the effect of 
EV was not mediated systemically [95].  
In the cancer field, intratumoral injection of EV as an anti-cancer treatment strategy has 
been greatly explored. Indeed, some biodistribution studies reported unmodified EV to be 
unsuccessful in tumor-specific delivery upon i.v. administration [96] [97]. Alternatively, direct 
injection of EV into tumors has been shown to be a much more effective anti-tumor therapy. 
Indeed, the work of Smyth et al. suggests that the intratumoral injection of DIR-labeled EV 
derived from 4T1 cells allows much higher retention of the vesicles inside the tumor, than 
their i.v injection in the tail [11]. Furthermore, intratumoral EV injection has been reported 
as efficacious in tumor growth inhibition. In the work of Martins-Marques et al., EV loaded 
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with luciferin and the chemotherapeutic agent doxorubicin, were injected in mouse tumors. 
Tumor growth was then monitored by bioluminescence imaging and a cytotoxic effect 
specifically in tumor cells was demonstrated. Interestingly, they concluded the presence of 
the gap junction protein connexin43 (Cx43) embedded in EV membrane improved the release 
of EV content into target cells, contributing to the reduction of cardiotoxicity of free 
doxorubicin injected systemically [98]. Intratumoral injection may be generally associated 
with reduced toxicity in non-target tissues. However, similar results using local or intravenous 
administration have also been reported [46].  
Although intratumoral EV injection is apparently more effective in tumor eradication, this 
type of administration is much more invasive than systemic administration, and thus unlikely 
to be as well accepted by patients [83]. In addition, it is not easily applicable for the 
treatment of tumors in deep body locations. However, injectable systems are also being 
developed that may facilitate delivery by minimally invasive surgery, and when surgery is 
required, for example for removal of the tumor, a delivery system could be implanted for the 
removal of cancer cells potentially remaining at the site. Indeed, a recent study by Palamà et 
al. leads us to speculate that an approach similar to the one they followed may be applicable 
for EV delivery. The authors reported the use of a poly-ε-caprolactone scaffold loaded with 
the anti-inflammatory drug dexamethasone in the treatment of osteosarcoma based on pre-
and-post-operative surgery [99]. Results demonstrated a sustained drug delivery and thus, a 
good strategy of localized tumor therapy.  
Another route of EV local administration often used is the subcutaneous injection. 
Investigations have shown that administration of EV by subcutaneous injection may be an 
effective anti-cancer treatment. An interesting study suggested the use of EV derived from 
M1-polarized macrophages as a cancer subcutaneous vaccine adjuvant [100]. A melanoma 
mouse model was used, and EV were injected subcutaneously in their right flank. To verify 
the EV distribution after administration, they were labeled with the lipophilic fluorescent dye 
Dil. Using an in vivo imaging system after animal’s sacrifice at 7 days after injection, EV were 
localized in inguinal and axillary lymph nodes near the injection local. This observation 
suggests that EV did not achieve systemic circulation in the lymphatics but mainly 
accumulated in lymph nodes near the place of injection, where they promoted an increase in 
the secretion of proinflammatory cytokines [100]. 
Since EV efficiency is dependent on their administration route, Hao et al. compared 
effects of EV administered via subcutaneous injection and via intradermal injection in 
antitumor immunity. This was performed in a mouse model with induced tumors in the tights. 
To monitor their distribution upon administration, EV were labeled and, despite the proximity 
of both injection routes to the tumor, by the intradermal route, labeled EV were detected in 
3.8 % of lymph nodes cells, against only 0.9 % of cells when subcutaneous route was used. 
These results are in agreement with the mice survival rate upon the two different 
administration routes: intradermal route demonstrated to be more successful in antitumor 
immunity than subcutaneous administration [101]. Interestingly, the first clinical trials (phase 
I) using EV performed repeated injections of EV, derived from autologous dendritic cells (DC), 
into melanoma and non-small cell lung cancer patients using the intradermal (10 % of the 
dose) and subcutaneous routes (90 % of the dose). Nonetheless, only modest antitumoral 
effects were achieved [102]. More recently, a phase II clinical trial for the treatment of non-
small cell lung cancer used conventional chemotherapy, combined with DC-derived EV for 
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cancer treatment. In this trial, EV were administered exclusively by intradermal injection 
leading to an increase of 32 % in the progression-free survival of patients [103]. Importantly, 
Dai and his team developed a Phase I clinical trial whereby EV derived from ascites of 
colorectal cancer, were subcutaneously administered to test their effectiveness in colorectal 
cancer treatment. Patients tested received EV only, or EV combined with GM-CSF. Both were 
shown to be safe, but only patients who received EV with GM-CSF developed an antitumor 
cytotoxic T lymphocyte response [104]. 
In the area of tissue repair and regeneration, subcutaneous injection of EV has also been 
reported. Komaki et al. injected subcutaneously placental tissue-derived EV into auricular 
wounds. They observed the capacity of this therapy to enhance angiogenesis in the murine 
auricle wound model [105]. In a mouse model of fat graft, animal flanks were subcutaneously 
injected with fat tissue, simultaneously with EV derived from normal or hypoxia pre-
conditioned adipose tissue-MSCs, or with PBS. The subcutaneously administration of EV and 
fat tissue lead to an improvement in graft survival and integration, compared to control 
flanks injected with fat and PBS, suggesting the subcutaneous route of administration can be 
used for local EV administration and effects [106]. 
Zhang et al. demonstrated the ability of weakly intra-articular administrations of human 
MSC EV to repair critically-sized osteochondral defects in rat models. After 12 weeks, 
regeneration was observed with hyaline cartilage and subchondral bone very similar to the 
original one [61]. As demonstrated by this study, short-term repeated doses of EV should be 
administered during the regeneration process to achieve good results. This kind of EV delivery 
is not comfortable for a patient, and is pointed as one of the major drawbacks of this 
approach, for clinical application [107]. 
Although there are not many studies using this type of administration, intracavernous 
injection was performed by Chen and his team to demonstrate EV effects in erectile 
dysfunction. The EV used were derived from adipose stem cells, and tested in a type 2 
diabetes mellitus rat model. Results showed an improvement on erectile dysfunction in rats, 
by decreasing apoptosis of penile tissue. Despite positive results, many issues were unclear in 
this study, namely how long EV remained in the organ, what was the EV dose administered 
and the specific time of their administration, and what was the mechanism of action [108]. 
Depending on the therapeutic action intended and the tissues to be targeted, different 
routes of administration of EV can be chosen. Overall, this choice will determine the 
pharmacokinetics and biodistribution of administered EV. Further modulation of these 
parameters might be achieved by EV incorporation into delivery systems as further discussed 
in the next section.  
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1.3 – Delivery Systems: from Drug to EV Delivery 
 
A drug delivery system (DDS) is a system that is used as a media or carrier for 
administering a pharmaceutical product to a patient, to achieve a therapeutic effect [109]. 
Similarly to free pharmaceutical products, DDS may be administered in patients either by 
parenteral routes (e.g., intravenous, subcutaneous, intramuscular, intranasal, etc.) or 
gastrointestinal routes (e.g., oral, rectal, etc.), requiring different features to reach their 
target. Moreover, different profiles of drug release from DDS may be desired depending on 
the action intended. With this in mind, many different DDS have been developed, and include 
nanoparticles, liposomes, microspheres, gels, scaffolds, among many other formulations 
[110]. An important characteristic that must be achieved by the different DDS synthesized is 
the controlled release of the pharmaceutical products they carry. Different sustained drug 
release formulations have shown that a long-term exposure of the tissue to a certain drug 
concentration is better than an increase of drug concentration, to achieve the pretended drug 
effects. Most of them intend to avoid a burst release and a concentration decay in blood 
[111].  
Local and systemic delivery of free EV do not allow to control the retention at the target 
site, consequently impairing the achievement of therapeutic concentrations. Also, the 
“pharmacokinetics” and biodistribution of delivered EV is neither controlled nor fully 
clarified. This issue may be overcome by the incorporation of vesicles into appropriate 
delivery systems that permit a timely and controlled release of EV in vivo. Controlled release 
will increase EV availability in the injury site for longer periods, maximizing their effect. In 
fact, EV have been used in combination with biomaterials of different types in a tissue 
engineering approach to treat several different lesions.  
Hydrogels constitute the class of biomaterials most used for EV delivery in vivo. In fact, 
they are very attractive for EV incorporation, since their mechanical properties can be tuned 
into a large extent by different techniques, including by using biocompatible cross-linkers 
[112]. Thus, hydrogels with very small pores may be synthesized, providing a slow release 
rate of the vesicles. A gradual degradation of the material makes a prolonged release 
effective, and decreases side effects of bulk and fast EV administration, such as accumulation 
in non-target organs [113] [114]. Moreover, they can be easily modified with different 
moieties for improved nanoparticles attachment to the hydrogel, which may be translated to 
EV. Most importantly, hydrogels can be administered by different methods, including 
injection [112]. 
Zhang et al. reported the use of human MSCs-derived EV in the therapy of traumatic brain 
lesions in rats. In that work, the EV were incorporated into three-dimensional type I collagen 
scaffolds to mimic the extracellular matrix. When compared to the controls used (liposomes 
mimicking the primary lipid / phospholipid content of the EV), there was an increase in 
angiogenesis and neurogenesis, as well as a decrease in neuroinflammation [115].  
Also, Liu et al. tested the incorporation of EV isolated from cultures of human iPS-derived 
MSC in a photoinduced imine crosslinking hydrogel glue, useful for cartilage repair due to its 
biocompatibility, and its capacity of cartilage integration. This approach has many advantages 
when compared to other EV administration modes, such as the ability of retaining EV in the 
cartilage defect site or the ability of achieve an accurate fit and even distribution in 
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irregularly shaped tissue defects. To monitor EV release from the glue, vesicles were labeled 
with the lipophilic fluorescent dye Dil prior to incorporation in the biomaterial, and release 
conditions were then simulated in vitro. Released EV could be detected by nanoparticle 
tracking analysis and red fluorescence of Dil-labeled EV were found in the cytoplasm of 
chondrocytes also entrapped in the glue, suggesting a successful endocytosis of the released 
EV. With this approach, the authors could demonstrate a released of about 100 million EV/mL 
every day, resulting in a major therapeutic dose to the surrounding cells [107].  
EV delivery using biomaterial scaffolds has also been reported, particularly in recent 
studies. Huang et al. reported positive effects of EV derived from dental pulp cells on 
odontogenic differentiation in vivo and in vitro. In this study, EV were isolated and embedded 
in collagen sponges, and included on the root canal space [116]. Another study compared the 
effects in osteogenesis of EV/β-TCP combination scaffolds with only pure β-TCP scaffolds. EV-
incorporating scaffolds were more effective in the bone repair on a rat critical-sized calvarial 
bone defect model, with large amounts of de novo bone formation [117]. In a recent work, 
Xie and colleagues functionalized decalcified bone matrix scaffolds with MSC-derived EV and 
investigated the angiogenic and osteogenic potential of these constructs in vivo. Regenerative 
potential of this scaffold was evaluated in a model of ectopic subcutaneous bone formation in 
nude mice. EV enhanced bone formation and increased vascularization in the grafts [118]. 
Chitosan-based materials have also been reported as delivery system for EV. A recent 
study demonstrated the use of chitosan hydrogel loaded with EV derived from miR-126-3p-
overexpressing synovium mesenchymal stem cells (SMSCs) in wound repair. The material 
incorporating EV was implanted on the wound bed, providing a controlled release of the 
vesicles, and was monitored daily until day 14 after surgery. The results demonstrated that 
release of SMSC-miR-126 EV increased re-epithelization, deposition of collagen and generated 
new vessels and their maturation at the wound site [119]. Another study reported similar 
results with chitosan/silk hydrogel loaded with gingival mesenchymal stem cells derived EV in 
in vivo experiments. As the previous study, a diabetic rat was tested and positive effects on 
the diabetic rat skin wound repair were verified [120]. In an innovative approach, Huleihel et 
al. tested ECM bioscaffolds, produced by decellularization of connective tissue, as natural EV 
carriers. They found that EV naturally anchored in the native matrix could survive the 
decellularization protocols applied and, when implanted, could promote cell growth and 
proliferation, cell migration and cell differentiation. They also showed that EV have specific 
miRNA signatures associated to their source tissue, essential information to improve clinical 
applications [121]. 
Despite the good functional results reported so far, the use of carriers for EV delivery is 
still little explored, and advantages and disadvantages of these systems, compared with free 
EV administration, are not yet well characterized. For instance, studies addressing 
biodistribution and pharmacological kinetics parameters of EV entrapped in scaffolds are very 
limited. Another point that needs to be clarified is how the controlled release of the EV from 
these scaffolds is achieved in vivo. Many characteristics of scaffolds composition and 
structure may be tuned for optimal controlled release of EV from different origins, such as 
scaffold porous size, interconnectivity between porous, method of EV adhesion to the carrier, 
among others. Thus, in the near future, it is necessary to improve the design of carriers to 
use with EV.  
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In the scope of this thesis, delivery system synthesized with chitosan and poly-gamma-
glutamic acid was developed for the entrapment of EV. The advantages of using such a system 
will be discussed in the next section. 
 
1.3.1 - Chitosan and poly-γ-glutamic acid: Biomedical Applications 
Ch is a linear polysaccharide that contains copolymers of β-(1→4)-linked D-glucosamine 
(deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit). It is a natural polycationic 
polymer obtained by the partial deacetylation of chitin, readily available from insects and 
crustaceans. It is biodegradable, biocompatible and nontoxic [122]. 
 Research based on nanotechnology and polymer science have been showing great 
advances in the use of chitosan-based films in strategies such as coating, extrusion, layer-by-
layer assembly, among others. For example, in food industry, chitosan-based films are being 
used for packaging [123]. In the environmental field, chitosan is a great alternative to 
synthetic pesticides, being used in the synthesis of environmentally friendly pesticides, 
contributing to a sustainable agriculture [124]. In the health sciences field, chitosan has been 
investigated as an antimicrobial agent, a blood anticoagulant and as a biomaterial in wound 
dressings, stent coatings, antibacterial coatings, biosensors, systems of controlled drug 
delivery and tissue engineering, including bone regeneration [122] [124] [125] [126] [127]. 
Usman et al. reviewed several chitosan-based materials and their potential application in the 
biomedical field [126]. Importantly, Food and Drug Administration (FDA) approved chitosan 
for tissue engineering and drug delivery. This biopolymer was also approved as safe by FDA for 
wound dressing applications and for dietary use [128]. Moreover, many cytotoxicity studies 
have been performed in order to clarify chitosan biodegradability and biodistribution in vivo, 
further supporting its safety [129]. 
 Poly-glutamic acid (PGA) is a polymer of glutamic acid that can be distinguished in two 
isoforms, based on the carboxy group establishing the monomers bonding: α-PGA or γ-PGA, if 
the attachment is on carboxy group α or γ, respectively. Due to its characteristics, only γ-PGA 
will be described in more detail for the purpose of this work.  
Poly-gamma-glutamic acid (γ-PGA) is naturally produced by several gram-positive 
bacteria, mainly from Bacillus species [130]. Contrarily to chitosan, it is an anionic polymer. 
It has good biodegradability, biocompatibility, water solubility and non-toxic effects [131]. Its 
use has been reported in food supplements and pharmaceutical. Its potential toxicity has 
been investigated [132]. Prodhomme et al. reported no toxic effects on the human B-cell line 
EHRB, and no toxicity after injection of 1 mg γ-PGA in a mouse model [133]. Hence, γ-PGA 
has been gaining importance in biomedical applications.  
 
1.3.2 – Chitosan as a delivery system 
Depending on their application, chitosan-based DDS can be used in many different 
formulations, mainly as nanoparticles or microparticles, hydrogel scaffolds and films. 
Importantly, for every chitosan-based DDS synthesized, many parameters can be modified in 
order to achieve specific characteristics in the final structure. They include the chitosan 
concentration used, the pH of the chitosan solution, the solvent used, the method chosen for 
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the synthesis of the structure, the use of chemically-modified chitosan derivatives, and the 
inclusion of crosslinking agents. Modification of any of these parameters affects the 
physicochemical properties of the chitosan structures, their mechanical properties and their 
porosity. Consequently, these modifications affect also the enzymatic degradability of 
chitosan and their biodistribution in vivo [134].  
Several methods can be used to produce drug-loaded chitosan nanoparticles. 
Nevertheless, its low solubility in biological fluids and its insolubility in organic solvents are 
limitations for the synthesis of formulations. To overcome this problem, chitosan DDS may be 
synthesized in acidic conditions and, more interesting, derivatives with improved 
hydrophilicity have been developed [135], by modifying chitosan by N-substitution, O-
substitution or free radical graft copolymerization [136]. Chitosan-based DDS have been 
reported for the delivery of labile molecules, such as peptides/proteins. For instance, 
incorporation of insulin in chitosan microparticles was tested, using tripolyphosphate (TPP) 
and glutaraldehyde as chitosan cross-linking agents. Incorporation of glutaraldehyde during 
microparticle synthesis was proven to be effective in preserving insulin activity [51]. 
Chitosan nanoparticles have also been investigated for the delivery of nucleic acids. 
Chitosan positive charge interacts with their negative charge, resulting in a polyelectrolyte 
complex, which protects the nucleic acids from degradation [135]. Chitosan particles have 
also been used for the delivery of different drugs. For instance, Zhang et al. tested the use of 
different carboxymethyl chitosan derivatives to function as nano DDS for docetaxel. Results 
suggested different physicochemical characteristics of the nanomaterials, such as different 
released profiles and cell cytotoxicity, with O-carboxymethyl chitosan exhibiting the 
strongest cytotoxicity against tumor cells [137]. In another study, Jain et al. realized that 
glutaraldehyde-crosslinked chitosan nanoparticles loaded with variable concentrations of 
docetaxel had a drug profile release in vitro that could be divided in 3 phases. Firstly, a burst 
release of the drug was observed, mainly from the surface of nanoparticles, secondly, there 
was a controlled drug release from the matrix, and finally, a steady release was reported, 
due to polymer degradation. Overall, about 68-83 % of loaded docetaxel was released, 
significantly decreasing viability of cancer cells in vitro, compared to blank control 
nanoparticles [138]. 
 In addition, loaded chitosan micro/nanoparticles may also be integrated in more 
complex DDS. A recent study produced aspirin-loaded chitosan nanoparticles incorporated in 
an asymmetric collagen-chitosan membrane. This delivery system was used in a critical-sized 
cranial defect on rats, and results showed an effective controlled release of the drug along 
time [139]. Also in this context, Karri et al. incorporated curcumin in chitosan nanoparticles 
that were then loaded into a collagen scaffold. Results in vitro showed an effective 
controlled drug release. In vivo results show enhanced wound closure when compared to the 
placebo scaffold groups and the administration of free curcumin [140].  
Besides being effective in the controlled release of many different compounds, chitosan 
particles have also a biodistribution pattern in vivo that favors their use as DDS in specific 
applications. As nanoparticles could be detected in bone marrow, chitosan nanoparticles may 
be usable for bone imaging and targeting strategies. However, it should be noted that 
nanoparticle biodistribution is greatly dependent on particle size. Nanoparticles with less 
than 5 nm diameter are usually removed by renal clearance due to their capacity to pass 
through the glomerular membrane. On the other side, nanoparticles with a diameter larger 
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than 200 nm are typically eliminated by the reticuloendothelial system. Thus, nanoparticles 
between this size range (5-200 nm) avoid both clearance mechanisms and can circulate in 
blood for a longer period [141].  Interestingly, exosomes size range is within these values. 
Chitosan can also be processed into hydrogels and scaffolds, three-dimensional 
crosslinked polymer networks with the ability of retaining large quantities of water. Due to 
their capacity to transport molecules and drugs, chitosan hydrogels are extensively studied 
for biomedical applications [142]. Chitosan-based hydrogels have been used for different 
purposes, including immunomodulation, cancer treatment and tissue engineering. In this 
field, Nafee and colleagues created a chitosan-based thermogel loaded with alendronate, a 
drug used in the treatment of bone conditions that has low effects when free administered 
orally. It was possible to modulate thermogel properties, for example, by increasing 
alendronate concentration, which resulted in a hydrogel with higher density and lower 
porosity. Previous work from our group has used chitosan scaffolds alone and in combination 
with pro-inflammatory molecule, fibrinogen, or inflammation resolution mediator, resolvin, 
to promote bone regeneration [143]. Furthermore, a combination of chitosan with β-
glycerophosphate resulted in a hydrogel with a time sustained drug release in vitro, up to 65 
days [144]. Despite their hydrophilic nature, chitosan hydrogels have also been tested for the 
delivery of hydrophobic drugs. This was achieved by functionalization with hydrophobic 
moieties. Marin et al. used palmitoyl glycol chitosan to incorporate the model hydrophobic 
drug denbufylline [145]. Chitosan may also be combined with other materials to tune their 
drug delivery properties. A 2003 study reported for the first time the development of a 
bilayer chitosan-gelatin scaffold with different pore size by changing the pre-freezing plate 
temperature and concentration of chitosan-gelatin solution. Indeed, a lower concentration of 
the solution increased the pore size [146]. The use of gelatin, due its viscosity, helped 
preventing drug leakage and, the cationic density of gelatin increased at pH ≈ 4, contributing 
to a firm gel formation.  
More recently the field of chitosan-based-self-healing hydrogels became of great interest. 
A self-healing hydrogel can self-reconstruct after its injection, allowing the simultaneous 
delivery of drugs of interest. Li and colleagues demonstrated that a chitosan-self-healing 
hydrogel was more effective in delivering an anti-tumor drug (Taxol), than a chitosan 
hydrogel [147]. 
More complex compounds may also be incorporated into chitosan hydrogels. Venkatesan 
et al. produced chitosan hydrogels with carbon nanotubes and tested their antimicrobial 
activity. The use of free carbon nanotubes is limited due its dispersion, but their 
incorporation in the chitosan hydrogel revealed to be a great strategy, greatly improving the 
antimicrobial activity of the nanotubes in a dose-dependent manner [148]. Nanoparticles and 
microparticles may also be loaded into a chitosan scaffold. A recent study demonstrated the 
effect of chitosan-hyaluronic acid nanocomposite scaffold loaded with antioxidant and anti-
inflammatory Andrographolide lipid nanocarrier in the enhancement of wound healing. A 
controlled release of the drug was achieved up to 72 h. This approach proved to have 
potential in wound healing applications [149].  
Chitosan can also be processed into films by solvent casting, usually followed by a 
crosslinking agent [150]. Films have many great characteristics, such as edibility, 
biocompatibility, non-toxicity and low cost. This chitosan formulation represents an 
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important form for drug delivery, due to the mucoadhesive properties of this biomaterial and 
their capacity to open epithelial tight junctions. These are great characteristics that 
promoted the investigation of chitosan as a DDS for the gastrointestinal system and skin, and 
as a coating material for other biomaterials [135]. Varshosaz and colleagues investigated the 
release of lidocaine from a crosslinked chitosan film to, in a future approach, deliver 
lidocaine into the oral cavity (for the treatment of oral mucositis) [151]. Importantly, this 
study confirmed that chitosan films crosslinking improves their physical and mechanical 
properties, thermal stability and water resistance, allowing their application onto other 
biomaterials [142]. 
 
 
1.3.3 – Poly-γ-glutamic acid as a delivery system 
As for chitosan, γ-PGA has been explored for the synthesis of DDS. The most common 
formulations include nano/microparticles and hydrogels. It was previously demonstrated that 
PGA molecular mass influences its drug delivery properties [130]. In addition, γ-PGA DDS may 
be combined with other biomaterials, rendering them suitable for different applications. 
Aguirre et al. produced poly(D,L-lactide-co-glycolide) acid (PLGA) nanoparticles for 
doxorubicin delivery and modified its surface with γ-PGA and folic acid. Importantly, at pH 
7.4, only 12 % of doxorubicin release was observed, which suggests this system as a good 
therapeutic vehicle for cancer [152]. In another study, the effect of caboxymethyl 
chitosan/PGA microparticles loaded with Levofloxacin as a hemostatic in wound dressings was 
verified. This system was demonstrated to be pH sensitive and a sustained release profile of 
levofloxacin was achieved in in vitro drug release experiments. Thus, this mechanism has 
potential to be a candidate carrier for drug delivery system [153].  
PGA-based injectable hydrogels for drug delivery were also previously reported. Ma and 
colleagues formulated a hydrogel with hyaluronic acid and poly-γ-glutamic acid carrying 
bovine albumin as a drug model. Results showed a sustained albumin release behaviour in in 
vitro experiments, which was reduced by hydrogel crosslinking degree [154]. In a previous 
study, a DDS system was produced by mixing PGA with a small quantity of chitosan, resulting 
in a vehicle with a thermo-sensitive behaviour with sol-gel transition at body temperature. 
This platform was used for the loading of human bFGF, which had a controlled release both in 
in vitro and in vivo. This release profile could be explained by the positive charge of bFGF 
that allows electrostatic interaction with PGA. Thus, a slow PGA degradation allowed a slow 
bFGF release [155]. 
 
1.3.4 – Combining chitosan and poly-γ-glutamic acid in a layer-by-layer 
delivery system 
The combination of chitosan cationic characteristics, with anionic polymers such as γ-
PGA, has been studied in our group for several years. Pereira et al. investigated the capacity 
of chitosan and γ-PGA to assemble into nanoparticles by using a co-acervation method [156]. 
Another investigation reported the incorporation of diclofenac in chitosan and γ-PGA 
nanoparticles and its release at physiological pH [157]. Moreover, considering the 
electrostatic interactions that are established between these polymers, we investigated their 
potential for the synthesis of layer-by-layer (LbL) self-assembly systems for drug release. 
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Antunes et al. demonstrated that chitosan could interact electrostatically with γ-PGA and 
developed a structure with a maximum of six alternated layers composed by chitosan or γ-
PGA [158]. A similar approach was reported by Cardoso et al., which synthesized chitosan and 
γ-PGA self-assembled polyelectrolyte multilayer films by using a LbL method. They further 
used this system for the delivery of IFN-γ in vitro, that was proven to be able to maintain 
protein structure and could retain high amounts of the cytokine. In addition, the assembly 
process could be made in the absence of organic solvents, improving the biocompatibility of 
this delivery system [159]. 
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1.4 – Objectives 
EV are important players in cell communication and, as discussed above, are promising as 
new therapeutic strategies for different diseases. Nonetheless, their clinical application is 
being impaired, among other factors, by their rapid clearance upon administration and broad 
body biodistribution. Hence, it was hypothesized that EV entrapment in a DDS could control 
local vesicle dose and bioavailability along time after administration. Thus, the main goal of 
this thesis was to develop an EV delivery system that could be used for the controlled release 
of the vesicles upon local administration in vivo. In order to achieve our aim, three main tasks 
were delineated:  
1. Select a human immune cell line for the production of EV at high yield and optimize 
cell culture conditions for EV production and isolation. 
In vitro cell culture conditions for EV production were optimized for the human immune 
cell lines KG-1, THP-1 and Jurkat. EV were isolated from cell culture supernatants and 
characterized.  
 
2. Develop an EV delivery system.  
A chitosan 3D scaffold was synthesized and functionalized with chitosan/γ-PGA in a layer-
by-layer system, in which EV could be entrapped. EV entrapment was confirmed by laser 
scanning confocal microscopy, and their release from the scaffold was studied in physiological 
conditions simulated in vitro.   
 
3. Determine the effect of EV entrapped in the chitosan-based delivery system on the 
modulation of human MSC phenotype. 
The 3D delivery system developed was used for EV entrapment and delivery in vitro to 
human MSC cultures. The effect of entrapped EV on modulating MSC migration, motility and 
differentiation was tested by transwell migration assay, time-lapse video microscopy, and 
gene expression analysis, respectively.  
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Chapter 2  
 
 
Methods and Materials 
 
 
 
2.1 - Cell culture  
 
In this work, we tested 3 different human leukemia cell lines – KG-1, THP-1 and Jurkat - 
to select the most adequate for EV production with high yield.  
THP-1 and Jurkat cells growth medium was RPMI-1640 (Corning), supplemented with heat 
inactivated Fetal Bovine Serum (FBS) 10 % (v/v) (Biowest) and penicillin/streptomycin (P/S) 1 
% (v/v) (Invitrogen). KG-1 cells growth medium was IMDM (Life Technologies), with the same 
supplements described above. FBS heat inactivation was performed by incubation at 57 ºC, 
for 30 min. All cells were grown in 75 cm2 cell culture flasks (BD Falcon) until confluence, and 
maintained at 37 ºC with 5 % CO2. After unfreeze, cells were used until a maximum of 8 
passages, to avoid major changes in their original [160] characteristics. Importantly, cells 
were subjected periodically to tests for mycoplasma contamination, and found to be 
negative. 
For EV production cells were cultured in EV producing media: RPMI or IMDM media 
supplemented with FBS 10 % or 0.1 % and P/S 1 %, previously ultracentrifuged (at 100 000x g, 
for 2 h, at 4 ºC).  
Functional assays were performed using human primary multipotent mesenchymal 
stromal/stem cells (MSC), isolated from the tibia of patients undergoing knee surgery. All 
procedures were previously approved by the Ethics Committee of Centro Hospitalar São João. 
MSC growth media was DMEM (Corning) supplemented with MSC-qualified heat inactivated FBS 
10 % (v/v) (Gibco) and penicillin/streptomycin 1 % (v/v) (Invitrogen). Cells were seeded in 175 
cm2 cell culture flasks (BD Falcon) until confluence, and maintained at 37 ºC with 5 % CO2. 
MSC from passage 4 to 7 were used in this work. MSC were previously characterized for the 
presence/absence of characteristic surface markers, and for their differentiation potential, 
and found to follow the criteria defined by ISCT for MSC definition [161].  
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2.2 – Cell viability Assays  
 
KG-1, THP-1 and Jurkat cells were seeded in EV producing media, in duplicate in 6-well 
plates, at a density of 2x106 cell/well/2 mL of media. Cells were incubated at 37 °C for 48 h, 
and representative optical photographs were taken at 0 h, 24 h and 48 h. After the 48 h, cells 
were collected, washed with phosphate buffered saline (PBS), and stained using the Annexin 
V/PI cell apoptosis kit (BD Falcon), according to the manufacturers instructions. Briefly, cells 
were incubated for 15 min, on ice, in Binding Buffer 1x containing Annexin V-FITC (2 L in 250 
L) and Propidium Iodide (PI; 5 L in 250 L). Then 250 L Binding Buffer 1x were added and 
cells analysed in a FACSCalibur flow cytometer, acquiring 10 000 events. Unstained cells and 
matched IgG isotype control were used to determine background controls. Data was analysed 
using FlowJo software and late apoptotic/dead cells defined as AnnexinV+PI+ double positive 
cells. 
 
 
2.3 - EV production, isolation and characterization 
 
2.3.1 – EV production and Isolation  
For EV production, cells were incubated at a density between 2x105 and 3x105 cells/mL, 
for 48 h, in EV producing media. After 48 h, cell culture media was collected and centrifuged 
at 2000 g, for 20 min, at 4 ºC; the supernatant was recovered and centrifuged at 10 000 g, for 
20 min and 4º C and the supernatant was again recovered and ultracentrifuged at 100 000 g, 
for 2 h, at 4 ºC, in a Beckman Optima L80-XP ultracentrifuge. The resulting supernatant was 
used as control (SN1), and the obtained pellets were resuspended in PBS pH 7.4 or in Tris 
NaCl-HCl pH 5, as indicated. For EV washing, resuspended EV pellets from different tubes 
were added together and ultracentrifuged again in the same conditions as before. EV pellet 
was resuspended in PBS pH 7.4 or Tris NaCl-HCl pH 5, and ultracentrifugation supernatant 
collected to use as control (SN2). All samples were stored at – 80 ºC. 
 
2.3.2 - EV characterization  
EV produced were characterized by Transmission Electron Microscopy (TEM), Nanoparticle 
Tracking Analysis (NTA) and western blot.  
For TEM, EV were adsorbed on 400-mesh formvar nickel grids and negatively stained with 
uranyl acetate 5 % for 2 min. Then, samples were analysed in a Jeol JEM 1400 electron 
microscope.  
To evaluate EV concentration, NTA was performed. In short, EV suspensions were diluted 
1:100 in 1 mL of filtered PBS 1x and then analysed in a NanoSight NS300 with NTA3.0 
software.  
Protein markers were tested by western blot, specifically CD63, an endosomal protein 
marker highly used for EV characterization, and calnexin, a protein marker of the 
endoplasmic reticulum, and which should be absent from EV. Ultracentrifugation 
supernatants and parent cell lysates were used as controls. Samples protein amount was 
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quantified using DC™ Protein Assay (Bio-Rad), following the manufacturer instructions. 
Samples were then prepared in non-reducing conditions, denatured at 65 ºC during 15 min 
and loaded in a SDS-PAGE 10 % polyacrylamide gel (Bio-Rad). Resolved proteins were 
transferred to nitrocellulose membranes. Membranes were blocked with non-fat milk, and 
then incubated overnight, at 4 ºC, with primary antibody anti-human CD63 (BD Pharmingem™) 
or anti-human calnexin (Abcam). On the next day, membranes were washed and incubated 
with HRP-conjugated secondary antibody (GE Healthcare). Membranes were then incubated 2 
min with ECL substrate (from GE Healthcare) for the development of a chemiluminescent 
signal, that was detected with autoradiographic films.  
 
 
2.4 – Production of EV delivery system 
 
The EV delivery system developed consisted of a chitosan scaffold functionalized with a 
chitosan/poly-γ-glutamic acid/EV Layer-by-Layer, and was produced in three main steps. 
First, chitosan, chitosan scaffolds and poly-γ-glutamic acid were produced, and then scaffolds 
were functionalized with a Layer-by-Layer system along with EV incorporation. All steps are 
described in detail in sections 2.4.1, 2.4.2 and 2.4.3. 
 
2.4.1 – Chitosan scaffolds production 
Chitosan 3D scaffolds were prepared by freeze-drying, as previously described by our 
group [162]. Briefly, a 2 % (w/v) chitosan solution was prepared by hydration of chitosan with 
Milli-Q-water, overnight at 4 ºC, followed by dissolution in acetic acid 0.2 M, overnight at 4 
ºC. The solution was centrifuged (5000 rpm, for 5 min) for air bubbles removal, and casted in 
48-well plates. Plates were then frozen at -20 ºC, overnight, in a flat surface, and freeze-
dried at -80 ºC for 48 h. The scaffolds obtained in each well, were removed from the plate 
and cut in the shape of cylinders with 2 mm diameter and 2 mm height with appropriate 
cutting material, as depicted in Figure S1.  
The obtained scaffolds were disinfected and re-hydrated by impregnation under vacuum 
with a gradient of ethanol solutions, under sterile conditions. Firstly, scaffolds were 
incubated with absolute ethanol for 10 min, then ethanol 70 % for 30 min for disinfection, and 
finally with ethanol 50 % and 25 %, for 10 min each. Scaffolds were then washed two times 
with Tris NaCl-HCl pH 5 and kept in this solution at 4 ºC until further use. All solutions used 
were filtered with 0.22 µm filter.  
 
2.4.2 – Poly-γ-Glutamic Acid production 
With the aim of producing chitosan sponges with chitosan-PGA layer-by-layer coating, γ-
PGA production was required. 
Poly-γ-Glutamic Acid was produced as previously described by our team [156]. The γ-PGA 
isolated in this work was produced by Bacillus subtilis IFO3335. B.subtilis were thawed and 
grown in Luria Broth (LB) solid medium with 1.5 % Agar. Colonies were picked, grown in liquid 
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Luria Broth media until reaching the exponential phase of growth, and then inoculated into γ-
PGA producing media. 
To isolate γ-PGA, culture medium was centrifuged at 12 000 g, for 1 h at 4 ºC. The pellet 
with cells was washed with NaCl 0.14 M. The supernatant of first and second centrifugations 
was recovered, the pH of this solution adjusted to 3.0 with H2SO4 6 M and then incubated at 4 
ºC for 12 h, with the aim of eliminating polysaccharides. The solution was then filtered with 
filter paper and mixed into three volumes of ethanol 99 % for protein precipitation, followed 
by centrifugation at 13 000 g for 10 min at room temperature (RT). The pellet was 
resuspended in Tris-HCl buffer 0.2 M pH 8.0 and the resulting solution dialyzed (MWCO: 10 
KDa) against Tris-HCl buffer 10 mM pH 8.0, at RT, for ~18 h. The dialyzed solution was 
lyophilized at -80 ºC for 3 days, and then dissolved in 8 mL of Tris-HCl buffer 10 mM pH 8.0. 
The solution was centrifuged at 12 000 g for 1 h at RT and then, the supernatant incubated 
with 20 µL/mL of proteinase k for 12 h at 37 ºC to promote α-peptides removal. After the 12 
h, the solution containing γ-PGA was dialyzed against ultrapure water for ~18 h and then 
lyophilized. The dry matter was weighted for yield assessment, and then resuspended with 
ultrapure water. To confirm the molecular weight (Mw) of the γ-PGA isolated, an SDS-PAGE 
was performed. γ-PGA samples were prepared in reducing conditions and resolved in a 
NuPAGE Bris-Tris polyacrylamide gel. The gel was then stained with Alcian Blue basic dye, for 
visualization of blue bands containing the anionic γ-PGA. 
 
2.4.3 – Scaffolds functionalization with a chitosan/γ-PGA Layer-by-Layer 
system  
Chitosan scaffolds were cut to the appropriate size and shape, before being combined 
with Ch and γ-PGA to make a multilayered system. These systems were prepared by the 
dipping method [163], consisting in the alternate immersion of chitosan 3D scaffolds in Ch 2 % 
and γ-PGA 0.2 mg/mL solutions at pH 5, according to the diagram in Figure 2.1. Between 
each layer, the scaffolds were washed with Tris NaCl-HCl pH 5 for 5 min. For EV incorporation 
into the system, 1x1010 EV from KG-1 cells (per scaffold) were mixed with the γ-PGA solution. 
Alternatively, the same volume of the washing ultracentrifugation supernatant (SN) was 
entrapped in the system and used as control.   
The final LbL systems had in total 6 layers, 3 of Ch and 3 of γ-PGA. All the steps were 
performed under vacuum and in sterile conditions.   
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Figure 2.1 - Scheme of synthesis of the LbL system on Ch scaffolds. From the left to the right, are 
represented the solutions applied, under vacuum, for the construction of the system in each chitosan 
scaffold. EV (or ultracentrifugation supernatant) were diluted in the γ-PGA solution due their negative 
charge. Washes were performed with Tris NaCl-HCl, pH 5. 
 
 
2.5 – Delivery system characterization 
 
2.5.1 – Confocal microscopy 
To confirm EV entrapment in the LbL system, EV were previously stained with the dye 
PKH26. Briefly, EV were labelled with PKH26 0.5 µM dye (Sigma Aldrich), for 5 min at 37 ºC. 
Excess free dye was then washed with PBS in VivaSpin® centrifugal columns (10 kDa cut-off). 
Red-labelled EV were entrapped in the LbL system as described in section 2.4.3. 
Functionalized scaffolds were then immersed in Vectashield mounting media and imaged by 
laser scanning confocal microscopy (LSCM; Leica TCS SP2 or SP5). Images were then processed 
for Z-projections in Fiji software. Importantly, the same acquisition settings were used for all 
conditions. 
 
2.5.2 - FTIR 
EV entrapment was also tested by Attenuated total reflection-Fourier-transform infrared 
spectroscopy (ATR-FTIR), in a FTIR Spectrometer Frontier (PerkinElmer). All measurements 
were done at room temperature. Functionalized and non-functionalized hydrated scaffolds 
were placed on the ATR accessory and compressed against it to achieve a flat contact 
between the sample and surface crossed by the analysis beam. Films of EV, SN, chitosan and 
γ-PGA solutions were also dispensed on the ATR accessory and spectra acquired. After data 
acquisition, a background correction was performed, and spectra of Tris NaCl-HCl films was 
subtracted from samples spectra. 
 
2.5.3 – EV release assay 
To evaluate EV release from the LbL system over time, release assays were performed. 
Briefly, after chitosan sponges functionalization with the LbL system, scaffolds were 
incubated in 250 μl PBS 1x (pH 7.4), at 37 °C and 300 rpm. The scaffold was transferred to 
new tubes with PBS 1x, at different time points: 0 h, 12 h and 24 h. The supernatant of each 
timepoint was then concentrated on VivaSpin® centrifugal columns with 100 kDa cutoff, by 
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centrifugation at 2500 xg, for 15 min. Concentrate was resuspended and preserved at -80 ºC 
until analysis by TEM, performed as described in section 2.3.2.  
 
 
2.6 – MSC transwell recruitment assay 
 
The capacity of EV to promote MSC recruitment was evaluated by transwell migration 
assay (Figure 2.2), as previously described by our team [164]. Briefly, transwell assays were 
set up in 24-well companion plates (bottom compartment; Figure 2.2A) with inserts (top 
compartment; Figure 2.2A) containing membranes of 8 µm-pore size (BD FalconTM). Due to the 
limited space between the bottom and top compartment for the placement of the chitosan 
scaffolds synthesized, inserts were elevated using eppendorf tubes lids, as depicted in Figure 
2.2B.  Inserts were coated with 100 µL bovine gelatin (1% (w/v), 1 h, 37º C), washed with PBS 
1x and then seeded with 0.2x106 MSC. Chitosan scaffolds alone or chitosan scaffolds 
functionalized with LbL system, with or without KG-1 EV or ultracentrifugation supernatant 
from EV pellet wash (SN), were placed in the bottom wells, as depicted in Figure 2.2A. KG-1 
EV and SN, and FBS 30 % (v/v) were used as controls. Serum-free DMEM was used in the assay. 
MSC were allowed to migrate for 12 h and then inserts were fixed with paraformaldehyde 4 % 
(w/v). The inside of insert membranes were cleaned from non-migrated cells using cotton 
swabs and washed with PBS 1x. Membranes were cut from the inserts, mounted on slides, and 
nuclei of migrated cells labelled using Fluoroshield with DAPI mounting media. Number of 
migrated cells was quantified by high throughput imaging using the IN Cell Analyzer 2000, 
followed by image processing using IN Cell Investigator software (both GE Healthcare). 
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Figure 2.2 - Transwell migration assay setup to test MSC migration in the presence of different stimuli. 
(A) Schematic representation of the transwell system used to test MSC migration. The delivery system 
with entrapped KG-1 EV or ultracentrifugation supernatant (SN), chitosan scaffolds functionalized with 
LbL system only, chitosan scaffolds alone, or KG-1 EV or SN only were added to the Bottom 
Compartment (BC), and used as a chemoattractant stimuli gradient for MSC migration. MSC were seeded 
in the inserts containing membranes of 8 µm-pore size (Top Compartment, TC), and allowed to migrate 
for 12 h. (B) Representative photograph of the 24-well plate used for the migration assay. So that the 
insert did not touch the scaffolds placed in the BC, sterile microtube caps were placed between wells to 
create height and thereby allow a higher position of the inserts. 
 
 
2.7 – Timelapse MSC motility assay 
 
As an alternative method to test MSC motility under the influence of different stimuli, 
6x103 cells/well were seeded in 24-well plates (bottom compartment), using MSC growth 
media (Figure 2.3). In the following day, media was replaced by serum-free DMEM (SFM) or 
MSC growth media previously ultracentrifuged and diluted to a FBS concentration of 1% (v/v). 
Inserts with 8 µm-pore size membranes (BD FalconTM) were placed on the wells (top 
compartment) and chitosan scaffolds alone or chitosan scaffolds functionalized with LbL 
system, with or without KG-1 EV or SN, were placed inside the inserts. Cells were then 
imaged by time-lapse video microscopy in an IN Cell Analyzer 2000 (GE Healthcare), for 12 h, 
in a controlled environment at 37 °C and 5% CO2. Brightfield images from different fields of 
each well were taken every 10 minutes over 12 h. All images were converted to a time-lapse 
video using FIJI software and single cell movement analysed with MTrackJ plugin for FIJI 
software. The total distance travelled per cell for each condition was determined.  
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Figure 2.3 - Schematic representation of the system used for MSC motility assay in the presence of 
different stimuli. MSC were seeded in the wells of a tissue culture plate (bottom compartment). After 
24 h, the delivery system with entrapped KG-1 EV or ultracentrifugation supernatant (SN), chitosan 
scaffolds functionalized with LbL system only or chitosan scaffolds alone were added to inserts 
containing membranes of 4 µm-pore size, that were placed in the wells (Top Compartment, TC). Cells 
were directly stimulated with KG-1 EV or SN for control. The described system was incubated in an IN 
Cell Analyzer 2000 for 12 h and images were obtained by time-lapse video microscopy, in order to 
evaluate MSC motility.  
 
 
2.8 – MSC differentiation assay 
 
The potential of KG-1 EV to enhance MSC differentiation was assessed by gene expression 
analysis, as previously described by our group [63] [165]. A total of 8x104 cell/well MSC were 
seeded in 6-well plates (bottom compartment; Figure 2.4) using MSC growth media. After 24 
h, cell culture media was changed to DMEM supplemented with FBS 1 % (v/v) (Biowest) and 
P/S 1 % (v/v) previously ultracentrifuged. Inserts with 4 um-pore size membranes (top 
compartment; Figure 2.4) were placed on the wells and chitosan scaffolds alone or chitosan 
scaffolds functionalized with LbL system, with or without KG-1 EV or SN, were placed inside 
the inserts. Cells were stimulated with KG-1 EV or SN alone as control. Osteogenesis inducing 
media, consisting of DMEM supplemented with FBS 1% (v/v) (Biowest), P/S 1% (v/v), 
dexamethasone 10-7 M, β-glycerophosphate 10−2 M and ascorbic acid 5×10−5 M (all supplements 
from Sigma-Aldrich) was used as positive control. Chondrogenic inducing media consisting of 
DMEM 4.5 g/L glucose supplemented with ascorbic acid 5×10−5 M (Sigma-Aldrich), proline 40 
mg/mL (Sigma-Aldrich), sodium pyruvate 100 µg/mL (Gibco), Insulin-Transferrin-Selenium 100 
µg/mL (Corning), dexamethasone 10-7 M (Sigma-Aldrich) and TGF-β3 (R&D Systems) was also 
used as positive control.  
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Figure 2.4. Schematic representation of the transwell system used to test MSC differentiation in the 
presence of different stimuli. The delivery system with entrapped KG-1 EV or ultracentrifugation 
supernatant (SN), chitosan scaffolds functionalized with LbL system only or chitosan scaffolds alone 
were added to the Top Compartment (TC). Cells were directly stimulated with KG-1 EV or SN for 
control. The influence of the stimuli on MSC differentiation seeded in the Bottom Compartment was 
evaluated by gene expression analysis after 3 and 7 days.  
 
At day 3 and day 7 after stimulation, cells were lysed with TRIzol (Invitrogen). For gene 
expression analysis, RNA was extracted following the manufacturer protocol, quantified by 
NanoDrop ND-1000 (ThermoFisher Scientific) and its integrity analysed by agarose gel 
electrophoresis (Figure S2). DNA was digested using a TURBO DNA–free Kit (Life Technologies) 
and cDNA synthesized using random hexamers and SuperScript® III Reverse Transcriptase (Life 
Technologies), following manufacturer protocol. Quantitative real time PCR (RT-qPCR) was 
performed using SYBR green-based assays, using SYBR Green PCR Mastermix (Bio-Rad), diluted 
cDNA template, and gene specific forward and reverse primers. The sequence of the primers 
used is in Table 2.1. RT-qPCR reactions were performed in a iQ5 Real-Time PCR Detection 
System (Bio-Rad), according to the following conditions: denaturation for 3 min at 95 ºC, 
followed by 40 cycles of cDNA denaturation at 95 ºC for 30 s, annealing at 58 ºC for 30 s and 
extension at 72 ºC for 30 s. A melting curve of 81 cycles with a temperature decrease step of 
0.5 ºC in 30 s, until 55 ºC are reached, was generated at the end of the run to assess primer 
specificity. PCR products were also analysed by agarose gel electrophoresis (Figure S3). 
GADPH was used as a reference gene and relative gene expression calculated by the Cq 
method.  
 
Table 2.1 - Sequence of the primers used in the RT-qPCR analysis performed on MSC, for the genes 
RUNX2, SOX9 and GAPDH. 
Gene Primer sequence 
RUNX2 Forward: 5’- CCTGAACTCTGCACCAAGTC -3’  
Reverse: 5’- GAGGTGGCAGTGTCATCATC -3’ 
SOX9 Forward: 5’- TTCCTCCTGCCTTTGCTTGT -3’  
Reverse: 5’- CGTGCTTGAAACATTCCCAGAAC -3’ 
GAPDH Forward: 5’- CCTCAAGATCATCAGCAAT -3’  
Reverse: 5’- CCATCCACAGTCTTCTGGGT -3’ 
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2.9 – Statistical analysis 
 
Data were analyzed using GraphPad Prism 5.02 (GraphPad Software, Inc.). Normality of 
data distribution was first analyzed using the D'Agostino and Pearson omnibus normality test. 
For comparisons of multiple groups of non-normal data, the Kruskal-Wallis test, followed by 
Dunn’s multiple comparisons test was used. For analysis of time-lapse video microscopy data, 
a Two-way ANOVA test, followed by Tukey’s multiple comparisons test was used. Statistical 
significance was considered for p-value<0.05.   
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Results 
 
 
 
3.1 – Optimization of cell culture conditions for EV production 
 
The yield and characteristics of EV depend on the cell population producing them [166] 
and on the culture conditions used [167]. Here, we sought to find a human immune cell line 
that would produce high amounts of EV in low serum concentrations, to help reduce protein 
contamination of isolated EV. In this work, two immune cell lines of myeloid lineage – KG-1 
and THP-1 -, and one immune cell line of lymphocytic lineage – Jurkat – were tested for their 
production of EV.  
Before EV production, KG-1, THP-1 and Jurkat cells were cultured in media with different 
serum concentrations, namely standard conditions with media with FBS 10 % (v/v), 
ultracentrifuged media with FBS 10 % (v/v), and ultracentrifuged media with FBS 0.1 % (v/v). 
Cells were monitored for up to 48 h in these culture conditions. Results illustrated in Figure 
3.1  show an increase in the number of cells in culture along time, for all cell lines and in all 
the culture conditions tested, indicating that even low FBS concentrations are adequate for 
cell proliferation. After the 48 h cells were harvested and stained for Annexin V and PI, to 
determine if there was any increase on the percentage of cells undergoing apoptosis (Annexin 
V+) or late apoptotic/dead cells (Annexin V+PI+). Results are illustrated in Figure 3.2A, and 
quantified across different experiments in Figure 3.2B. The viability of the KG-1 and THP-1 
cell lines was found unaffected by the use of ultracentrifuged FBS, even when it was reduced 
to 0.1 %, with no detectable differences in the percentage of Annexin V+ apoptotic, or 
Annexin V+ PI+ dead cells in any of the conditions tested. On the other hand, viability of the 
Jurkat cell line was maintained in ultracentrifuged FBS, but was decreased when the 
percentage of serum was reduced to 0.1 %, when comparing to standard FBS conditions, 
although this difference was not statistically significant. Thus, KG-1 and THP-1 cells were 
cultured in media with 0.1 % ultracentrifuged FBS for EV production, while Jurkat cells were 
cultured in media with 10 % ultracentrifuged FBS. 
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Figure 3.1 – Morphology in culture of all tested cell lines. KG-1, THP-1 and Jurkat cells were cultured at 
the density of 3x105 cell/mL in media with different conditions of serum concentration (10 %, 10 % 
ultracentrifuged (UC) and 0.1 % UC), and photos were taken in different time points (0 h, 24 h and 48 
h). Scale bars: 0.2 mm. (n=3 independent experiments).  
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Figure 3.2 - Characterization of cell viability of the three cell lines tested, when cultured in different 
serum conditions. (A) Representative Annexin V vs Propidium Iodide flow cytometry dot plots for all 
cells and serum conditions tested, after 48 h of cell culture. (B) Percentage of Annexin V+/PI+ double 
positive cells in the different serum conditions, representing the percentage of cell death. No statistical 
differences were found by Kruskall-Wallis statistical test (n= 3 independent experiments). 
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3.2 – Immune cell EV secretion and characterization 
 
After cell culture conditions optimization, EV from each cell line were isolated by 
ultracentrifugation as previously described and performed in our lab [63]. EV pellet washing 
with PBS 1x was also tested in order to remove non-EV contaminants. Then, washed and non-
washed EV were characterized for their morphology, size and protein markers, using TEM, 
NTA and western blot. The results obtained are detailed in Figure 3.3. The TEM analysis shows 
successful isolation of EV for all cell lines tested, with the characteristic cup-like morphology 
and a size under 200 nm (Figure 3.3A). With this analysis, it was possible to perceive a more 
contaminated preparation, with protein aggregates (dark spots), in the images obtained for 
the EV isolated from Jurkat cell line. Also, we could verify that the supernatant from the first 
ultracentrifugation contained more protein and lipid clusters, than that of second 
ultracentrifugation, as expected. Data of size distribution and concentration were obtained 
by NTA and the results are shown in Figure 3.3B and Figure 3.3C, respectively. NTA data 
reported an average size of 200 nm for EV derived from KG-1 cells, and around 150 nm for EV 
derived from THP-1 and Jurkat cells (Figure 3.3B). EV concentration was higher for non-
washed EV populations isolated from KG-1 cells (more than 2.0x1011 particles/mL), than 
isolated from the other cell types (around 1.0x1010 particles/mL for THP-1 and 1.5x1010 
particles/mL for Jurkat), as showed in Figure 3.3C. Importantly, EV pellet washing seemed to 
lead to a great loss of EV, except for Jurkat cells (Figure 3.3C), but without increased particle 
number in the supernatants. Western blot was also performed to analyze protein markers, 
namely CD63 as an exosome marker and calnexin as an ER marker, that should be negative on 
EV. According to the results presented in Figure 3.3D, CD63 was enriched in EV of KG-1 and 
Jurkat, relative to cell lysates and was present but not enriched in EV from THP-1, indicating 
the isolated EV populations were enriched in exosomes. No CD63 was detectable in the 
ultracentrifugation supernatants. In addition, analysis of calnexin confirmed the purity of our 
EV suspensions, free from cellular organelles like the ER, as it was only detectable in cell 
lysates, and was absent in EV (Figure 3.3D). 
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Figure 3.3 – Characterization of EV from KG-1, THP-1 and Jurkat cell lines. (A) Representative TEM 
images of EV and supernatants of the first ultracentrifugation (SN1) and the ultracentrifugation after the 
PBS wash step (SN2), for all cell lines tested. (B) NTA analysis of average EV size for each cell line 
tested. KG-1 EV size is around 200 nm, and for the remaining cell lines EV size is around 150 nm. (C) 
Concentration (in particle/mL) of EV isolated from all tested cell lines. KG-1 cell line, selected for 
further works, had the highest concentration of EV when compared to the other cell lines. (D) 
Representative western blot for detection of CD63 and calnexin in EV, ultracentrifugation supernatant 
before (SN1) and after EV pellet washing (SN2), and in cell lysates, for each cell line tested. 
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Considering the high yield of EV production by KG-1 cells, and preserved cell viability 
upon culture in low serum conditions comparing to the other cell lines, EV produced by KG-1 
cells were selected to be further used in our work. KG-1 cells were cultured and EV were 
regularly isolated using the standardized protocol that included a washing step. Washing and 
pellet resuspension was performed in Tris NaCl-HCl pH 5 in order to obtain EV suspensions 
suitable to be entrapped in the delivery system developed. A summary of the characterization 
results for the different EV pools is shown in Figure 3.4. For each cell culture batch, KG-1 cell 
viability was assessed at the time of EV isolation by trypan blue exclusion assay, and found to 
be always above 80 % (Figure 3.4A). TEM analysis of the isolated EV revealed the presence of 
a high amount of EV in vesicle preparations and no detectable protein contaminants (Figure 
3.4B). As expected, EV pellet washing with Tris NaCl-HCl helped to eliminate protein 
aggregates contaminants, as supported by the clear background (Figure 3.4B). Furthermore, 
EV could not be found in the washing ultracentrifugation supernatant SN2, revealing the 
efficiency of the EV isolation process used.  
NTA analysis of the EV isolated showed they have an average size of 150 nm (Figure 
3.4C). The average concentration of the EV suspensions was 2.3x1011 EV/mL (Figure 3.4D).     
 
Figure 3.4. Characterization of EV isolated from KG-1 cells. (A) Percentage of cell viability for each EV 
isolation (n=9 independent experiments). (B) Representative TEM images of EV isolated and the 
supernatant (SN2) resulting from the washing ultracentrifugation. Red arrows are pointing to EV, 
evidencing their cup-shape morphology. Scale bar: 100 nm, and 100 000 x magnification. (C) Size 
average of isolated EV population. (D) Number of EV per mL in the different EV pools made (n=3 
different EV pools).    
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3.3 – Delivery system component characterization 
 
For γ-PGA biosynthesis, B. subtilis was cultured following the procedure previously 
detailed in Chapter 2. γ-PGA colonies obtained are represented in Figure 3.5A. B. subtilis was 
cultured in γ-PGA producing media and the γ-PGA synthesized and secreted by the bacteria 
was isolated and purified. To estimate the molecular weight (Mw) of γ-PGA isolated, a SDS-
PAGE was performed and is depicted in Figure 3.5B. γ-PGA range its Mw from 20 to 50 kDa 
(Figure 3.5B). The final yield was ~200 mg γ-PGA/L of culture media.  
 
Figure 3.5. (A) B.subtilis culture in Agar. (B) SDS-PAGE to determine the Mw of γ-PGA produced. Lane 1 
corresponds to Mw standards, in kDa, as indicated, and the next lanes (2,3 and 4) were loaded with 
different amounts of γ-PGA (80 µg, 240 µg and 400 µg, respectively). 
 
On the other hand, chitosan scaffolds were produced by freeze-drying as previously 
described [162] and cut into 2x2 mm cylinders (Figure S1) for subsequent use in building the 
LbL system synthesis. EV were incorporated into the γ-PGA solution, due to their negative 
charge, and LbL with 6 layers (3 of Ch and 3 of γ-PGA) were produced. 
  
 
3.4 – Layer-by-Layer system is able to entrap EV  
 
After synthesis of the delivery system, entrapment of labelled EV was evaluated by LSCM. 
Results are illustrated in Figure 3.6, and show abundant red labelled EV incorporated along 
the scaffolds structure. As controls LbL were produced using labelled ultracentrifugation 
supernatant (SN) control or empty (just Ch and γ-PGA). Empty LbL showed no red 
fluorescence at all, and only a few red spots were detected in the scaffolds functionalized 
with SN-containing LbL. The red fluorescence of labelled EV was detectable around the 
chitosan structure, as expected if layers are being formed around the scaffold (Figure 3.6, 
higher magnification image). 
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Figure 3.6 - Layer-by-layer system with entrapped EV. Representative laser scanning confocal 
microscopy images of chitosan scaffolds functionalized with the LbL system and with entrapped PKH26 
(red) labelled EV (LbL+EV), or with PKH26-labelled ultracentrifugation supernatant (LbL+SN), or the 
system alone (LbL). A detail of entrapped EV on the surface of the Ch scaffold is shown in the higher 
magnification picture. Ch scaffold structure is visible in blue (autofluorescence). Scale bar: 100 µm. 
(n=2 replicates) 
 
As confocal microscopy does not have enough resolution to image each EV, we sought to 
confirm EV presence on LbL by complementary approaches. So, EV alone, LbL empty, LbL 
with SN and LbL with EV were all analysed by FTIR. The comparative analysis is presented in 
Figure 3.7 and shows very similar spectra for all the LbL containing samples, with no 
detectable peak shift due to the presence of EV. Thus, it is possible to verify a similar peak 
profile for LbL, LbL+EV and LbL+SN conditions. All these spectra present characteristic peaks 
of Ch. The absorption peaks at 1340 and 1280 cm-1 are characteristic of the C-N bond of 
amines I and II, respectively [168]. Although, the peak verified at approximately 870 cm-1 and 
1150 cm-1, corresponding to the saccharide structure.  In addition, peaks appearing at 1030 
and 1080 cm-1 are due to the vibration of the C-O bond. The peak observed at 1380 
correspond to the -CH group [168].           
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Figure 3.7 - FTIR spectra of EV-containing LbL systems. Representative images of the spectra obtained 
for the LbL + EV, LbL + SN, LbL alone and EV films. (A) Representation of all spectrum speaks (from 850 
cm-1 to 3500 cm-1). (B) Detailed visualization of the FTIR spectra in the wavenumber region between 
2700 and 3500 cm-1. (C) Detailed visualization of the FTIR spectra in the wavenumber region between 
850 and 1800 cm-1. (n=2 replicates)        
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3.5 – Layer-by-Layer EV release profile 
 
Next, we sought to analyse the release profile from the produced LbL. A release time 
course was set up and samples were collected at times 0, 12 h and 24 h of incubation at 
physiological pH, 37 ºC and under agitation. First, we tried to quantify the released EV by 
measuring the amount of protein in the supernatants at the different time points. Protein 
concentration is a commonly used method for EV indirect quantification, but the protein 
levels released from the LbL systems were bellow detection (data not shown). Thus, 
supernatants were concentrated and analysed by TEM for the presence of EV. Results are 
illustrated in Figure 3.8, and show that it was possible to detect EV at 12 and 24 h timepoints, 
in the samples released from LbL+EV, but not from control LbLs. Moreover, EV seemed to be 
present in larger amount at 12 h (Figure 3.8; boxes in red are identifying some of them).  
 
Figure 3.8 - EV release from LbL systems. Representative TEM images of the concentrated supernatants 
of the release assay at timepoints 0 h, 12 h and 24 h, for the LbL system with entrapped EV (LbL+EV), 
the control LbL system alone (LbL), and the LbL system with entrapped ultracentrifugation supernatant 
(LbL+SN). The presence of EV released from the LbL+EV at 12 h after incubation is highlighted by the 
red squares. Picture inset shows in detail the morphology of the EV released. Scale bar: 200 nm. 
Magnification: 80 000x. (n=1 experiment) 
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3.6 – Effect of EV from the delivery systems in MSC migration 
 
Our previous results show a significant capacity of DC-derived EV to recruit MSC [63]. 
Thus, we next investigated the capacity of LbL-delivered EV to recruit MSC, using a transwell 
migration assay performed as previously described in our team [63]. Human MSC were seeded 
on TC and their migration capacity tested in the presence of different stimuli added to BC. 
However, the assay presented some technical difficulties, due to the size of the delivery 
system, that was too tall for the transwell set up. An adaptation was made, as described in 
the methods section. Results illustrated in Figure 3.9A show an example of an insert 
membrane with migrated MSC nuclei represented in blue (DAPI staining). The number of cells 
migrated per membrane was counted, and results are illustrated in Figure 3.9B, showing low 
numbers of migrated cells for all the tested conditions. 
 
Figure 3.9 – MSC recruitment in a transwell migration assay, as influenced by different stimuli. (A) 
Representative image of the nuclei of MSC migrated through the transwell insert membrane (DAPI 
staining). Scale bar: 50 µm. (B) Quantification of MSC migration in the presence of different stimuli, 
namely Ch scaffolds alone, Ch scaffolds functionalized with LbL alone (LbL), or with EV (LbL+EV), or 
ultracentrifugation supernatant (LbL+SN). EV and SN alone were used as controls. Serum-free media 
(SFM) was used as negative control and FBS 30% was used as positive control. Statistical significance was 
tested by Kruskal-Wallis test, followed by Dunn’s multiple comparison test, and no differences were 
found. (n=2 independent experiments) 
 
As we could not exclude that the instability of the transwell system set up was 
conditioning the results obtained for MSC migration, we next evaluated the capacity of LbL-
delivered EV to impact MSC motility by time-lapse video microscopy. Results are illustrated in 
Figure 3.10A and Figure 3.10B, and quantified in Figure 3.10C. MSC motility was quantified 
from the location of the nucleus in image each frame. Results indicate that when LbL 
included EV, MSC moved significantly more and faster, when compared to all controls, LbL+SN 
and LbL alone (p<0.0001), and EV alone (p<0.001). In addition, MSC appear to move more in 
response to Ch, to the empty LbL, and to EV alone than in the negative control condition 
(SFM), albeit not significantly. These results suggest a synergistic effect of EV and LbL 
delivery system on MSC motility. As expected, 30% FBS also increased MSC motility compared 
to SFM (negative control), but to a comparable level of Ch and empty LbL, and to a much 
lower extent than LbL+EV (Figure 3.10C). 
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Figure 3.10 - MSC migration profile in time-lapse motility assays. (A) and (B) Representative image of 
some of the cell tracks determined. The videos obtained (by assembling the images obtained every 10 
minutes for 12 h) were examined with MTrackJ plugin in FIJI in order to determine the pathways 
travelled by each cell analyzed. Scale bar: 50 µm (C) MSC travelled distance in the presence of the 
following stimuli: Ch scaffolds alone, Ch scaffolds functionalized with LbL alone (LbL), or with EV 
(LbL+EV), or ultracentrifugation supernatant (LbL+SN), EV and SN alone. Serum-free media (SFM) was 
used as negative control and FBS 30 % was used as positive control. ***p<0.001 and ****p<0.0001, as 
calculated by 2-way ANOVA followed by Tukey’s multiple comparisons testing. (n=2 independent EV 
pools) 
 
 
3.7 – Functional impact of LbL-mediated EV delivery on MSC 
differentiation 
 
Finally, we investigated the influence of LbL delivered EV on MSC osteogenic and 
chondrogenic differentiation. A preliminary experiment was performed whereby MSC were 
exposed to LbL for 3 and 7 days, followed by RNA extraction for assessment of cell 
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differentiation by gene expression analysis of the levels of the osteogenic gene marker, 
RUNX2,  and the chondrogenic gene marker, SOX9 (Figure 3.11). 
 
Figure 3.11 – Osteogenic and chondrogenic differentiation of MSC in the presence of LbL with and 
without EV. (A) MSC differentiation profile, after 3 days of culture. MSC showed more RUNX2 expression 
in the presence of the produced delivery system with different conditions (LbL alone; LbL+EV; LbL+SN). 
SOX9 was higher with LbL+EV. EV and SN alone were used as control. Osteogenesis (Osteo) and 
chondrogenesis-inducing media (Chondro) were used as positive controls. (B) MSC differentiation profile, 
after 7 days of culture. Gene expression was normalized to GAPDH. (n=1 experiment) 
 
The results obtained show no significant impact of EV alone or entrapped in the 
delivery system on MSC differentiation (Figure 3.11). Nonetheless, at day 3, EV entrapment in 
the LbL system (LbL+EV) led to a slight decrease of RUNX2 expression by MSC, accompanied 
by an increase of SOX9 expression, compared to MSC in the presence of LbL alone or LbL+SN 
(Figure 3.11A). LbL-delivered EV also seemed to increase SOX9 expression compared to MSC 
stimulation with EV or SN alone. A slight increase in RUNX2 expression could also be observed 
for LbL+EV compared to EV alone, but to a lower extent than the osteogenic positive control 
50     Chapter 3 
 
 
 
(Osteo). As expected, MSC stimulation with osteogenic media increased RUNX2 expression and 
decreased SOX9, relative to basal conditions. However, MSC stimulated with chondrogenic 
media, did not show a high SOX9 expression compared to basal conditions, at day 3.  
 Moreover, at day 7 (Figure 3.11B), LbL+EV showed reduced SOX9 expression, 
comparing with LbL alone or LbL+SN, while maintaining RUNX2 at similar levels. These results 
suggest LbL+EV could stimulate MSC osteogenic differentiation along time. At day 7, RUNX2 
and SOX9 levels were similar for MSC stimulated with EV alone or entrapped, and the same 
was observable for SN. Contrarily to day 3, at day 7, Ch scaffold functionalization with LbL 
seemed to promote chondrogenesis as supported by a marked increase in SOX9 expression 
levels, compared to Ch alone and even to chondrogenic positive control (Chondro). From day 
3 to day 7, MSC stimulation with osteogenic media maintained RUNX2 expression levels, while 
slightly increased SOX9 levels. In addition, chondrogenic media greatly increased the 
expression of SOX9 while maintaining RUNX2 levels.  
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Discussion and future perspectives 
 
 
 
The main goal of this thesis was to develop an EV delivery system that could be used for 
the controlled release of the vesicles upon local administration. In order to develop and test 
such a system it was important to have a reliable source of abundant EV. Thus, we started our 
work by investigating several immune cancer cell lines for EV production, due to their fast 
proliferation in in vitro cultures. We chose 3 different leukemia cell lines: KG-1, human 
monocytes derived from a patient with acute monocytic leukemia; THP-1, also human 
monocytes obtained from a patient with acute myelogenous leukemia; and Jurkat, human 
lymphocytes derived from an acute T Cell leukemia patient. Our focus on leukemia cells lines 
was motivated by the fact that these cells produce abundant EV, and also previous results 
from our group demonstrating that EV from human immune cells influence MSC biology [63]. 
In order to isolate EV with reduced protein contamination we optimized the cell culture 
conditions for these cell lines. This was motivated by the fact that FBS-derived protein 
components are major contaminants in EV preparations, often misleading the interpretation 
of results regarding EV biological functions [169] [170]. When reducing FBS concentration, it 
was crucial that cells would not undergo apoptosis, which would contaminate our EV 
preparations with apoptotic vesicles. From the results obtained for the different cell lines 
cultured in reduced serum conditions, we concluded that, when Jurkat cells were cultured in 
medium with 0.1% ultracentrifuged FBS, their viability was affected, with increased cell 
death (double positive cells for both Annexin V and PI), when compared with the remaining 
cell lines in the same percentage of serum. The viability of myeloid cell lines THP-1 and KG-1 
cells was not affected by the reduced FBS concentrations. However, after isolation of EV for 
each of the cell lines, KG-1 cells were shown to secrete EV in a much higher concentration, 
when compared to THP-1 cells in the same culture conditions.  
The EV populations isolated from KG-1, THP-1 and Jurkat cell cultures were characterized 
by complementary standard techniques, commonly applied in the EV field [169]. EV isolated 
from all cell lines had a size and morphology within the range described for exosomes [171], 
carrying also the exosomal protein marker CD63, indicating that the isolated vesicle 
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populations were enriched for exosomes. In particular, KG-1-secreted EV presented a cup-like 
morphology and a size in the range of 50 – 200 nm. Of note, EV average size distribution could 
be obtained by NTA and TEM, showing concordant values for both techniques. According to 
NTA analysis, the average EV concentration obtained was 2x1011 particles/mL, which is a good 
yield compared with EV derived from other cell linages [172].  
After optimization of cell culture conditions for KG-1 EV production, the isolated EV were 
incorporated into the delivery system under development. The concept of LbL self-assembly 
has been devised several decades ago [173], and is increasingly reported in different 
formulations for potential biomedical applications, from implant coatings to drug delivery 
systems [174]. Briefly, a LbL system consists in an alternating deposition of oppositely 
charged polymers. It is an innovative system, since it allows the incorporation of high 
concentrations of biological drugs, that may include chemical compounds, proteins, nucleic 
acids and even particles [163]. In addition, this system allows a local and controlled delivery 
of the cargo it carries, for instance when the pH of the environment changes, and can be 
adjusted by changing the number of layers that compose it, or the architecture of the 
scaffold to be used [175]. Several studies have been exploring the synthesis of such system 
with the most varied polymers, including with chitosan [176], and for applications also in 
bone tissue engineering [175]. The work of this thesis was focused on the use of a pH 
sensitive LbL system with Ch and γ-PGA as a coating for Ch scaffolds. The negative charge of 
the γ-PGA allows it to have electrostatic attraction with positively charged polymers such as 
Ch [177]. Also, if the drug to be incorporated has a net positive charge at pH 5.5, it is 
incorporated in the Ch layer, while if its charge is negative, as is the case of EV, then it is 
incorporated in the γ-PGA layer. The combination of these two biomaterials had been 
exploited in bone regeneration field[177] [178], which motivated their choice for application 
in our system. Hsieh et al. showed that it is possible to combine them in a matrix with 
interconnected pores with effects on the adsorption of cells, advantageous for several 
applications in tissue engineering [177]. In another approach, the same authors associated a 
similar system with entrapped rhBMP-2 (a protein known to promote cartilage and bone 
regeneration), and a potential therapy for bone defect was proposed [179]. Previously in our 
group, Ch and γ-PGA have been successfully combined into a LbL system based on films 
deposition on 2D surfaces [158], and shown to be efficient for the controlled release of IFN-γ 
[143]. However, to the best of our knowledge, the coating of 3D Ch scaffolds with a Ch and γ-
PGA LbL was not previously reported. Thus, in the current work, we optimized this LbL 
system for the functionalization of 3D chitosan scaffolds, and also for the incorporation of 
more complex and bigger mediators than proteins, as is the case of EV.  
In order to visualize EV entrapped in the delivery system, we previously labelled them 
with the lipophilic dye PKH26, which has been used by us and others to label EV lipid bilayer 
and follow their internalization into cells [63] [180]. To ensure the specificity of the observed 
staining, SN control was labelled in the same way as EV, before incorporation in the LbL 
delivery system. The results obtained showed a few bright labelled dots in the control 
samples LbL with entrapped SN, which are likely dye aggregates, formed by PKH26 [181]. 
Nonetheless, presence of labelled structures in EV-containing samples were much more 
abundant and surrounding the chitosan scaffold. Several attempts were made to further 
confirm EV presence in LbL systems. However, FTIR analysis could not confirm the EV 
presence in the delivery systems, as the spectra of LbL+EV was similar to that of the controls. 
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Similar results were obtained by Tao et al., for the detection of EV incorporated into chitosan 
scaffolds [119]. This may be attributed to the small contribution of EV to the total 
composition of the delivery system, which includes a chitosan 3D scaffold further coated with 
Ch and γ-PGA. In fact, mainly peaks corresponding to chitosan are identifiable in the spectra 
obtained. Furthermore, chemical bonds present in EV components and in Ch are very similar, 
which hinders the success of this technique for the characterization of EV-containing LbL 
systems [182]. Also, SEM (Figure S4) and TEM microscopy approaches were previously 
attempted in the group, but without success, due to the irregularities of the scaffolds, which 
contribute to a high background with small spherical shapes that does not allow for a 
conclusive identification of EV. To overcome these difficulties, we will perform 
immunostaining of the EV entrapped in the LbL system using specific markers such as CD81, 
CD9, CD63, followed by fluorophore- or gold-conjugated antibodies and confocal or electron 
microscopy imaging, respectively. Other EV labelling methodologies can also be performed as 
alternatives, such as EV carrying Renila luciferase (Rluc) or stained with hydrophilic 
permeable compounds such carboxyfluorescein succinimidyl ester (CFSE) [183] [184].  
An important property of delivery systems is the release profile of the compounds they 
carry. Thus, the LbL system was tested for the release of EV in conditions that mimic a 
physiological environment, namely in terms of temperature, pH and fluids dynamics 
(agitation). In our test system, the physiological pH is particularly important, since it allows 
the disruption of the electrostatic interactions that were established between chitosan and γ-
PGA layers (at pH 5), and consequently, the release of EV entrapped. Our first approach to 
characterize the EV release was to quantify the amount of protein released along time. This 
was performed as quantifying protein amounts is an indirect measure of EV quantity, but the 
protein amounts released were bellow the detection limits of the tested protein 
quantification kits. Then we tried a qualitative approach, and focused on the detection of the 
vesicles in the supernatant of the release assay by TEM, at different timepoints after 
incubation in physiological-like conditions. Importantly, it was possible to confirm EV 
presence, particularly at 12 h of incubation. In order to better characterize the EV release 
profile, further experiments should be performed to analyse the release supernatants, both at 
earlier and later timepoints. In addition, the amount of EV loaded into the scaffolds could 
also be increased, in order to facilitate their detection by quantitative techniques, such as 
protein quantification and NTA, commonly employed to analyse EV concentration. Since we 
could detect less EV in release supernatants at 24 h after incubation, it is suggested that EV 
release from the system may be rather fast. On the other hand, since the bone regeneration 
process is a slow process, it could be important to increase the release time of EV, which 
could be achieved by increasing of the number of layers in the LbL system [163]. Another 
approach could be the use of blocking layers of less-diffusive polyelectrolytes (such graphene 
oxide) that can enhance the mechanical durability of the layers [163]. Although it was 
possible to observe released EV at 12 h and 24 h of incubation, this assay provided only a 
qualitative analysis. To obtain quantitative results, our next approach would be to resort to 
more sensitive and specific methods for detecting EV, for example, by using the ExoELISA Kit, 
which would allow a CD63 antibody-based quantification of EV, and indirectly assess the 
quantity of EV released [185].  
The ability of DC-derived EV to recruit MSC has been studied in our group [63] and is a 
very interesting feature for promoting bone regeneration, since these cells are able to 
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differentiate into osteoblasts, the bone-forming cell population. To confirm that EV delivered 
in the LbL system could maintain their functional properties, we investigated their capacity 
to promote MSC recruitment, using two different assays. The first consisted of a transwell 
recruitment assay, as previously used in our group to show EV recruitment potential [63]. 
However, in order to accommodate the size of the delivery systems, there was the need to 
perform a home-made adaptation to rise the inserts where MSC were seeded, and thus the 
experimental set up may have become unstable and potentially tilted (albeit this was not 
visible with the naked eye) influencing the MSC migration results. To circumvent those 
technical difficulties, we set up an alternative assay to test the capacity of KG-1 EV 
entrapped in the LbL delivery system to promote MSC motility, evaluating it by time-lapse 
video microscopy. This assay showed that EV-containing LbL were able to promote a 
significant increase in MSC motility, relative to all controls, including the LbL system alone or 
with entrapped SN, or the EV alone. The fact that the LbL system alone and the EV alone led 
to slight increases in MSC motility, albeit not significant, lead us to speculate that the effect 
observed with EV-loaded LbL systems results from the synergistic action of both. The effect 
observed for LbL alone is in accordance with previous observations, in which chitosan/γ-PGA 
LbL films promoted a slightly higher MSC migration than TCPS alone [186]. Finally, it should 
be highlighted that the capacity of KG-1 EV to promote MSC migration is in line with similar 
results we obtained for primary human DC-EV [63], and reported by others for MEC-1 
lymphocytic leukemia cell line [187]. Also, it is necessary to take into account that these 
results should be further validated by using more MSC donors. In addition, the delivery system 
should also be tested with EV isolated from human primary DC [63] or other human primary 
myeloid cell type, and not only from leukemia cells, since the effect of tumor immune cells 
upon MSC migration could be different from normal immune cells. Importantly, these results 
indirectly show that EV were in fact entrapped in the LbL delivery system, supporting our 
observations of labelled EV in the scaffold and our TEM results of EV release along time, also 
demonstrating that they remain functional upon release.  
Finally, we also tested the influence that KG-1-derived EV could have in the capacity of 
MSC to differentiate into the osteogenic and chondrogenic linage. These are important 
processes for bone regeneration, particularly by endochondral ossification, whereby a 
cartilageneous template is first formed and calcified along time to form new bone [188]. 
Thus, the gene expression analysis of RUNX2, a marker of early osteogenic differentiation 
[189], and SOX9, a marker of early chondrogenic differentiation, was performed. EV alone, do 
not seem to significantly affect MSC differentiation, since RUNX2 and SOX9 levels are similar 
to basal conditions at both timepoints tested. This is in agreement with previous results 
reported for the role of DC-derived EV in MSC differentiation [63]. On the other hand, EV 
entrapment seems to promote chondrogenesis compared to basal conditions at day 3, but the 
effect was not as noticeable at day 7. In addition, LbL alone seems to promote 
chondrogenesis, from day 3 to day 7, and thus an effect of LbL component materials on MSC 
differentiation, even in the presence of EV, cannot be excluded. This is in agreement with 
the literature, since the ability of these materials to promote new bone formation through 
endochondral ossification has already been reported [190]. Importantly, from day 3 to day 7, 
EV entrapment seems to promote MSC osteogenesis due to an increase of RUNX2 expression 
and a decrease of SOX9 expression. Of note, these results should be further validated for 
different MSC donors, in order to confirm our conclusions. Gene expression studies will be 
repeated and the effects at protein level will be evaluated by ALP activity and alizarin red 
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staining for osteogenesis, and Toluidine blue staining for chondrogenesis. Considering our 
results for the role of LbL+EV on MSC migration, this EV delivery system may be particularly 
adequate to promote bone regeneration. In fact, EV entrapped in LbL system greatly increase 
MSC motility, and the delivery system itself may promote MSC differentiation into the 
chondrogenic or osteogenic lineages, depending on presence or absence of EV respectively, 
and thus its implantation in vivo might promote MSC recruitment to places of bone injury 
followed by stimulation of their chondrogenic/osteogenic differentiation, enhancing bone 
regeneration.  
Altogether, the results presented above indicate successful EV entrapment in a Ch and γ-
PGA LbL system, assembled on 3D Ch scaffolds, and that those EV can be released and 
maintain their functional properties upon release. Our results support a beneficial effect of 
delivering entrapped EV, suggesting EV as chemoattractants for MSC, recruiting them to 
places of bone injury, where one can envisage the delivery system as enhancer of their 
differentiation, together promoting bone tissue repair and regeneration. In future studies, 
the contribution of LbL-delivered EV to bone regeneration should be validated, using in vivo 
models of bone injury, where this system could be implanted.  
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Supplementary information 
 
 
 
 
 
 
 
Figure S1 - Overview of all cutting steps of chitosan scaffolds until the desired size is achieved. (A) 
Chitosan scaffolds produced and equipment used to cut them. Chitosan scaffolds obtained by freeze-
drying were trimmed with the blade to obtain a cylinder with flat tops. These scaffolds were first cut 
into 8x4 mm (diameter x height) cylinders, that were then punched with a 2 mm puncher (in green in 
the figure), to obtain 2x4 mm (diameter x height) cylinders. These scaffolds were then cut in half with 
the blade, into the final shape of 2x2 mm (diameter x height) cylinders used for the assays. From left to 
right: sponge originally obtained in the wells of the plate where the Ch solution is casted and 
subsequently lyophilized; after cutting to a height of 4mm with the materials previously described; 
cylinder obtained with a height of 2mm and diameter of 2mm. (B) Representative images of the 
scaffolds with different heights, in the different steps until obtaining the desired scaffold size (2x2 
mm). 
 
 
 
 
 
 
Figure S2 – Representative gel image of RNA extracted analyzed by agarose gel electrophoresis. As 
expected, two bands corresponding to ribosomal RNA 28S and 18S (from top to bottom) are visible, 
confirming RNA integrity.  
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Figure S3 – Representative gel image of RT-qPCR products analyzed by agarose gel electrophoresis for 
RUNX2 in MSC stimulated with osteogenesis-inducing media (Osteo), SOX9 in MSC stimulated with 
chondrogenesis-inducing media (Chondro) and for GAPDH, RUNX2 and SOX9 in MSC stimulated with the 
LbL delivery system with entrapped EV (from left to right, respectively). Only one band was visible in 
each lane, and bands for the same gene but in different MSC-stimulating conditions had the same size, 
confirming the specificity of the primers used.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4 - Scanning electron microscopy analysis of scaffolds with entrapped EV, as previously 
performed in the lab. (A) Overview of chitosan 3D scaffolds functionalized with the LbL system alone 
(LbL), or with entrapped EV (LbL+EV), or ultracentrifugation supernatant (LbL+SN). Magnification: 10 
000x. Scale bar: 10um. (B) Detailed imaging of the surface of the chitosan scaffold with LbL, LbL+EV and 
LbL+SN. Magnification: 50 000x. Scale bar: 2um. For the analysis, samples were coated by Au/Pd 
sputtering and images were acquired on a Quanta 400 FEG ESEM / EDAX Genesis X4M High Resolution 
Environmental Scanning Electron Microscope with X-Ray Microanalysis and Electron Backscattered 
Diffraction. 
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Abstract  
Extracellular vesicles (EV), in particular exosomes, have been the object of 
intense research, due to their potential to mediate intercellular communication, 
modulating the phenotype of target cells. The natural properties and functions of EV 
are being exploited as biomarkers for disease diagnosis and prognosis, and as nano-
bio-carriers for the development of new therapeutic strategies. EV have been 
particularly examined in the field of cancer, but are also increasingly investigated in 
other areas, like immune-related diseases and regenerative medicine.  
In this review, the therapeutic use of EV as drug delivery systems is described, 
balancing the advantages and drawbacks of different routes for their in vivo 
administration. Systemic and local delivery of EV are discussed, tackling the persisting 
difficulties in the assessment of their pharmacokinetics, pharmacodynamics and 
biodistribution in vivo. Finally, we discuss the future perspectives for incorporating EV 
into delivery systems and their use for an improved and controlled release of EV in 
vivo. 
 
 
 
Keywords: exosomes, biodistribution, delivery system, nanoparticles. 
 
 
1. Introduction  
In the last decades, research on cell secreted Extracellular Vesicles (EV) has 
expanded exponentially. Their role in cancer has been by far the most described and 
explored, but their contribution to the processes of inflammation and tissue repair has 
also been under intense scrutiny. These have been recently reviewed by us [1].  
Three main classes of EV secreted by cells have been reported and 
characterized, based on their origin, release mechanism and properties: apoptotic 
bodies, microvesicles and exosomes. The last two types of vesicles have deserved 
most attention from the scientific community due to their biological properties [2]. 
Microvesicles originate from the plasma membrane and their size can range from 50 
nm to 1 μm. Exosomes are smaller, with sizes in the range of 40-100 nm, are derived 
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from the intraluminal bud of multivesicular endosomes (MVE), and are released after 
fusion of these MVE with the plasma membrane [3]. These nanovesicles are secreted 
by most types of cells, including tumour cells [4] [5], playing a key role in intercellular 
communication, without cell-cell contact. In this review, exosomes will be particularly 
emphasized. However, the exact distinction of these different vesicle populations is 
still controversial, and partly hindered by methodological limitations, and thus wherever 
appropriate the designation EV will be preferred. 
Upon secretion, the different types of EV are present in body fluids or 
supernatants of in vitro cell cultures, and thus to study each population, it is necessary 
to isolate them separately. Different methods have been developed and optimized, 
mainly intended to isolate exosomes, achieving different degrees of purity and yield. 
These methods include differential centrifugation with a final step of ultracentrifugation 
[6], ultracentrifugation in density gradients [6] [7], phase separation [8], size-exclusion 
chromatography [9] and immunoprecipitation, particularly based on the commonly 
used exosomal marker CD63 [6]. However, difficulties in isolating pure EV populations 
still persist, with most methods leading to the co-precipitation of non-EV contaminants. 
Consequently, it is of utmost importance that the vesicles isolated are extensively 
characterized, using standardized methods [10] [7] [11] [12]. So far, the main 
techniques used for EV characterization are transmission electron microscopy [6], [13], 
atomic force microscopy [14], nanoparticle tracking analysis [13] [15] [16], dynamic 
light scattering [17], flow cytometry (directly on EV or upon their capture on beads) and 
western blotting of common protein markers (e.g., CD63, CD81, CD9) [18] [19], and 
more recently, tunable resistive pulse sensing [13] [15], surface plasmon resonance 
[20], and Raman spectroscopy [21].   
Independently of their origin, EV are lipidic vesicles that carry a protein content 
in their core, as well as on their surface, and may also contain different types of RNAs, 
including messenger RNA and microRNAs (miRNAs), DNA, and even metabolites [22]. 
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Nonetheless, each type of EV has a detailed biomolecule signature. Importantly, these 
biomolecules are reported to be functional, when delivered to target cells [23] [24].  
In this way, EV have been reported to participate in different homeostatic 
biological processes, including delivery of active biomolecules to target cells, antigen 
presentation to trigger an immune response, and cell waste management, initially 
thought to be their only function [25]. They may also contribute for the spreading of 
infecting pathogens and pathologies, namely cancer metastasis [26]. EV have also 
been greatly explored as biomarkers of disease, because their composition is related 
to the cell from which they derive. Characterization of EV levels and composition in 
biofluids, particularly in blood, urine and saliva, can contribute for the diagnosis, 
prognosis and monitoring of therapeutics in various diseases, cancer being the most 
explored [17] [27] [17] [3, 28].  
EV have been increasingly investigated in the nanomedicine field, both as 
messengers in cell-cell communication and as intelligent systems for targeted delivery. 
Many studies have been reporting their use to deliver molecules such as miRNAs, 
siRNAs, proteins or drugs [2]. However, despite the increasing research in EV field, 
difficulties in their isolation, in terms of purity and yield, are obstacles to their successful 
translation into clinical applications. Furthermore, basic techniques for characterization 
of EV administered in in vivo models need substantial improvement, before going into 
clinical applications. The potential therapeutic role of EV makes it necessary to invest 
in quantification and characterization methodologies, before and after in vivo 
administration, in order to attain a fast and precise characterization of EV [15] [29]. On 
the other hand, it should be taken into account that EV are not retained for a long time 
in circulation when administered in vivo, reportedly due to the action of macrophages 
[30]. Furthermore, the mechanisms controlling the specific delivery of EV to a specific 
target are largely unknown and need to be further studied. Different approaches are 
being developed to overcome these barriers that limit the therapeutic use of EV, from 
vesicle functionalization to their incorporation into local delivery systems.  
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In this review, we discuss the different reported approaches for in vivo delivery 
of EV, including their systemic and local delivery, as vesicles suspensions or 
incorporated in more complex delivery systems. The limitations of each approach in 
terms of vesicles biodistribution and biological effects achieved are also appreciated. 
In parallel, different approaches to follow EV after administration in in vivo models are 
detailed. Finally, we compare the systems used for EV delivery with the ones 
commonly used for nanoparticles incorporation, suggesting some adaptations of the 
latter for the improved delivery of EV in vivo.  
 
2. Therapeutic potential of EV: The importance of delivery methods 
 EV nanosize and natural ability to transfer information between cells, renders 
them promising candidates to be explored as nanodevices for therapeutic applications 
[31]. 
Naturally, EV carry active biomolecules that are loaded into their core or 
incorporated in their membrane through endogenous cell-regulated mechanisms [32] 
[33] [3]. The content of EV constitutively secreted by a cell reflects its physiological 
condition. For instance, researchers previously showed that the RNA cargo of MSC-
derived EV is different according to tissue source [34]. Also, EV secreted by immune 
cells at different stages of activation may elicit either immunostimulatory or 
immunosuppressive responses in target cells [35].  
In order to improve the therapeutic potential and to standardize the effects of 
EV, research has been increasing both in the modification of the content of naturally 
produced EV, and on the production of synthetic EV by functionalizing liposomes or 
small unilamellar vesicles functionalization [36]. Much like with synthetic nanoparticles, 
different types of molecules, such miRNAs, messenger RNAs, siRNAs, proteins, and 
even drugs, can be incorporated into EV, which become guided transporters to target 
cells. EV have been loaded with different molecules, exogenously or endogenously. In 
the first approach, the molecule of interest is included into EV after isolation, while the 
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endogenous approach is based on active encapsulation, particularly during exosome 
biogenesis, via transforming the producing cells with the selected molecule [37]. Many 
studies have focused on strategies for EV modification, and in comparing their 
properties with those of lipid-based nanoparticles, thus it will not be addressed in detail 
in herein [1, 31, 38] . 
In cancer, EV have been explored for immunomodulatory therapies, or directly 
as anti-tumor therapies, as recently reviewed [7]. In fact, anti-tumor therapies based 
on anti-cancer drug loading on EV have been the most studied. For instance, EV 
loading with anti-mitotic drug Paclitaxel has been explored both by exogenous loading 
of the drug on isolated EV, that are then fed to the cancer cells [39], and by 
endogenous EV loading, using MSCs, which were previously loaded with Paclitaxel, 
to incorporate it during vesicle biogenesis [40]. Those studies reported that resulting 
EV decreased cell viability, and generated better cytotoxic effects than the free drug, 
which was mediated by EV internalization. Many other studies reported the use of 
chemotherapeutics loaded in EV, supporting their use as drug vehicles, and a good 
alternative/complement to traditional anti-cancer therapy. This is reportedly due to a 
great reduction in toxic side effects, since EV biodistribution to target tissues may be 
increased by choosing appropriate parental cells for EV production [41] [42].  
EV have also been reported for the development of new therapies for several 
diseases, including neurodegenerative disorders. Their reported ability to cross the 
blood-brain barrier (BBB) has been exploited in different studies. Haney et al. used EV 
to increase the levels of catalase in the brain of mice, resulting in neuroprotective 
effects [43]. Similarly, EV (from self-derived dendritic cells) decorated with Lamp2b 
protein and neuron-tropic peptide from the rabies virus glycoprotein (RVG peptide), 
and loaded with siRNA against BACE1 protein, were able to cross the BBB in mice 
upon intravenous administration, without non-specific effects in other tissues [44]. 
These studies and others highlight the promise for EV-based treatment of different 
neurodegenerative diseases. However, some issues need to be overcome to achieve 
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clinical trials. For example, the RVG peptide is exogenously expressed in EV surface 
in many studies targeting the brain, but the receptor for this peptide is often 
downregulated in Alzheimer’s disease [45].  
Although cancer and neurodegenerative disorders are the fields where EV 
research is most intense, using EV as drug delivery systems in other areas, such as 
tissue repair and regeneration, particularly of the heart, has also gained increasing 
attention, and has recently been reviewed by us [1].  
In the field of tissue repair, EV secreted by MSC have been the most studied 
for their regenerative capacity. Many studies have been demonstrating their positive 
effects on homeostasis recovery, as well as on the regeneration and repair of damaged 
tissues. This suggests a therapeutic effect of MSC-derived EV that can be used as an 
aid to various therapies [46] [47]. In particular, EV derived from umbilical cord MSC 
were explored in different contexts. For instance, to prevent acute graft-versus-host 
disease in a mouse model of allogeneic hematopoietic stem cell transplantation [38]. 
EV were intravenously administered, leading to a decrease in in vivo manifestations of 
acute graft-versus-host disease, along with decreased mortality [38]. Also, EV derived 
from umbilical cord-MSC were used to improve the fibrotic outcome of carbon 
tetrachloride (CCl4)-induced mouse liver fibrosis. After 3 weeks of treatment, epithelial-
to-mesenchymal transition of hepatocytes was inhibited and fibrosis ameliorated [48]. 
Many other studies used EV secreted by MSC from different tissues as delivery system 
for the treatment of the same model of CCl4-induced liver fibrosis in mouse, reporting 
an amelioration of the condition [49].  
Related to renal injury, Gatti et al. demonstrated significant effects in reduction 
of epithelial tubular cell damage in an ischemia rat model, by using MSC-derived EV 
[50]. However, clinical trials have not been performed yet, to demonstrate their effects 
in restoring the renal function in human chronic kidney disease [50]. EV derived from 
MSC were also shown to reduce infarct size in a mouse model of myocardial 
ischemia/reperfusion injury [51]. In a similar approach, Ibrahim et al. used EV from 
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human cardiosphere-derived cells in a chronic myocardial infarction murine model. 
Exosome administration inhibited apoptosis of cardiomyocytes and promoted their 
proliferation, helped by an increase of angiogenesis [52]. 
 The regenerative effects of EV from MSC were also reported in models with 
osteochondral defects [34]. In the study from Zhang et al., MSC-derived EV were intra-
articular administered in an osteochondral defect created on distal femurs of adult rats, 
and PBS treatment was used as a control. After 12 weeks, a full reparative response 
of the femurs was observed in exosome-treated rats. In addition, only fibrous repair 
tissues were found in PBS-treated rats. This was the first study reporting the positive 
effects of EV derived from MSC in cartilage repair [53]. On the other hand, recent work 
also showed that EV from dendritic cells are able to recruit MSC [54]. 
In the studies published so far exploring the therapeutic potential of EV in vivo 
and in clinical trials, the strategy for vesicle administration is highly variable, occurring 
by different routes and in different dosages. Furthermore, several EV-based therapies 
have been promoted for commercialization by several companies, for which EV dose, 
administration route, and timeplan of administration are undisclosed, and not well 
defined [55]. 
Depending on the target tissue/organ and the effect intended, EV have been 
delivered systemically or locally, and either as vesicle suspensions or incorporated in 
more complex delivery systems. In the next sections, we discuss the advantages and 
disadvantages of the different delivery routes, from clinical and therapeutic 
standpoints.  
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2.1. Strategies for EV systemic delivery 
To reach the target tissue or organ, EV can be administered via different routes, 
such as intravenous, intraperitoneal, oral, intranasal, and subcutaneous (Figure 1), 
that may lead to their systemic distribution. 
 
 
Figure 1. Strategies for EV administration in vivo. Studies with different animals 
models and also clinical studies with human subjects have been using different routes 
for EV administration, such as intranasal, oral, intravenous, intraperitoneal, 
subcutaneous, intratumoral, among others. The choice of the best route for EV 
administration route is mainly dependent on the target tissue and on the biological 
effect expected. Furthermore, it is related with the formulation used for EV preparation, 
which can be administered as free vesicles in suspension, or incorporated in a delivery 
system synthesized with different biomaterials that will allow their controlled release in 
vivo. These delivery systems include hydrogels, stiff scaffolds, decellularized matrices, 
among others. The use of the different routes for the administration of EV, and their 
preparation in different formulations, has been reported to lead to successful 
therapeutic effects. 
Intranasal	
Oral	
Intravenous	
Intraperitoneal	
Subcutaneous	
Intratumoral	
Administra on	 Therapeu c	poten al	of	EV		
Intravenous	route:	the	most	common	via	of	EV	systemic	administra on.	Reported	to:	
induce	an tumor	immunity	in	mouse	[58];	to	improve	animal	func onal	recovery	in	
brain	injury	[62,	63];	to	promote	heart	func on	recovery	[64];	to	reduce	infarct	size	
[51];	to	decrease	the	size	of	wounds	in	mice	[65].		
Formula ons	
Free	EV	
EV	loading	into	
biomaterials	
Intraperitoneal	route:	allow	the	loading	of	larger	EV	doses.	Described	to	have	an	
immunomodulatory	role,	decreasing	macrophage	infiltra on	and	expression	of	IL-6	and	
MCP-1	in	a	gra 	mouse	model	[72].		
Intranasal	route:	par cularly	interes ng	for	EV	delivery	into	the	brain,	surpassing	the	
blood-brain	barrier	[43,81].	Also	used	to	target	the	respiratory	tract,	with	EV	inducing	a	
tolerogenic	immune	response	against	air-borne	pathogens	[78].	
Oral	route:	is	a	convenient	administra on	route	for	pa ents.	Reported	to	delay	
arthri s	signals	and	decrease	levels	of	pro-inflammatory	cytokines	in	the	serum	[74];	
an -tumoral	ac vity	in	mice	[75,	76].		
Intratumoral	route:	Direct	injec on	of	EV	into	tumors	promote	a	higher	reten on	of	
vesicles	and	show	to	be	more	effec ve	in	an -tumor	therapy	[88,	89].	Reduces	the	
toxic	effects	of	many	chemotherapeu c	drugs	but	is	not	easily	applicable	in	the	
treatment	of	tumors	in	deep	loca ons	[73].		
Subcutaneous	route:	mostly	used	for	local	EV	administra on	[91,	97].	Reported	to:	
enhance	angiogenesis	in	the	murine	auricle	wound	model	[96];	lead	to	modest	an -
tumoral	effects	in	clinical	trials	with	pa ents	of	melanoma,	non-small	cell	lung	cancer	
and	colorectal	cancer	[92,	93,	95].				
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2.1.1. EV intravenous administration 
The most widely used strategy for EV in vivo delivery is the intravenous 
injection (i.v.), considered the fastest way to deliver drugs and also EV, due to their 
direct delivery to systemic circulation. In one of the earliest studies dedicated to 
determine EV biodistribution, reporter EV derived from HEK 293T cells were injected 
subcutaneously in athymic mice and their biodistribution followed by in vivo imaging 
[56]. These EV were coupled to Gaussia luciferase and biotin, allowing conjugation 
with labeled streptavidin for non-invasive in vivo fluorescence imaging, and also 
analysis of EV distribution by bioluminescence, including in biofluids such as blood and 
urine, upon the addition of luciferase substrate. As early as 30 min after administration, 
EV could be detected in liver and spleen of mice, being detected in low amounts in the 
brain, heart and muscle at all timepoints analyzed. In accordance, EV were detected 
at the highest concentration in blood at 30 min after administration, peaking in the urine 
at 60 min post-injection [56]. In a later work, Manca et al. tested the biodistribution of 
fluorophore-labeled milk-derived EV upon i.v. and oral administration. After 24h, EV 
administered i.v. accumulated in liver and spleen, while those administered by oral 
route accumulated only in small intestine [57]. The i.v. route has been used in the 
majority of the in vivo studies investigating EV as new anti-cancer therapies. For 
instance, i.v.-injected EV were already demonstrated to work as potent vaccines for 
induction of antitumor immunity in the mouse [58]. In one of the first studies performing 
EV administration i.v., EV ameliorated functional recovery in a mouse model of acute 
kidney injury [59]. Several other studies performing systemic i.v. injection have been 
successful in ameliorating different brain conditions, implicating that EV in circulation 
are capable of crossing the BBB [60] [61]. Indeed, in one of the first studies using 
siRNA-loaded EV, discussed above, EV injected intravenously, could reach the mouse 
brain, resulting in specific gene knockdown [44]. In further studies, MSC-derived EV 
injected in the tail vein were capable of improving animal functional recovery in 
traumatic brain injury [62] and cerebrovascular accident [63]. This capacity of EV to 
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readily reach the brain is a great advantage comparing to most synthetic delivery 
systems, that usually need to be functionalized in order to improve their penetrance 
across the BBB. The i.v. administration of EV has also been explored in the 
cardiovascular field, using vesicles of different cellular origin. In the study by 
Vandergriff et al. the authors show that EV isolated from cardiosphere stem cells 
cultures, when injected in the tail vain of mice with induced dilated cardiomyopathy, 
promoted heart function recovery by reducing apoptosis and fibrosis [64]. Furthermore, 
i.v. administration of EV derived from MSC were shown to reduce infarct size in a 
mouse model of myocardial ischemia/reperfusion injury [51]. The systemic 
administration of EV was also previously shown to improve local cutaneous wound 
healing. The recent work from Wang and colleagues suggested that EV derived from 
human adipose MSC decreased the size of incisional dorsal wounds in mice, upon 
intravenous injection [65]. 
Intravenous administration allows that EV reach their target anywhere in the 
body, even locations distant from the place of injection, like internal organs. However, 
the short half-life index of EV in circulation after injection is one of the major limitations 
of this route of administration [66]. Indeed, as demonstrated by several in vivo studies, 
EV are readily cleared from circulation, with some works reporting a calculated half-
life close to only 2 minutes [66]. Most commonly, EV are cleared to liver and lungs [66]. 
In a detailed study by Morishita et al., EV from B16BL6 melanoma cells were 
radioactively labeled and injected intravenously. By collecting blood and organs at 
different timepoints, and measuring radioactivity, the authors showed that, 30 min after 
injection, only 1% of injected EV were still in blood. At the same timepoint, almost 40% 
of the injected dose could be detected in the liver and 10% in the lungs, a distribution 
pattern that was specific for those vesicles [67]. In a follow-up study, the same group 
indicated that the rapid clearance of EV from circulation after i.v. injection was mainly 
driven by macrophages, resulting in the accumulation of injected EV in the liver [30]. 
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Although EV have a certain degree of specific tissue targeting, which is usually 
considered better than synthetic nanoparticles [68] [69], it is important to understand 
that EV clearance from circulation into different off-target organs might be an important 
drawback, for instance if vesicles are being used for the delivery of cytotoxic drugs. 
Furthermore, it is necessary to take into account that there are consequences of 
maladministration, which may be irreversible [3]. Indeed, serious consequences may 
occur when over-dosing EV is reached. For instance, Smith et al. reported a mouse 
died by asphyxiation with accumulation of EV in lungs, despite all the positive effects 
reported in regeneration of many organs [70].  
 
2.1.2. EV intraperitoneal administration 
Another common method of EV administration is via the intraperitoneal route. 
Studies like the one by Liu et al. performed intraperitoneal administration of EV to 
modulate the immune response to a vein graft performed distantly, in the carotid of 
mice [71]. In this work, EV isolated from adipose tissue-derived MSC cultures, and 
labeled with the PKH26 dye, were administered intraperitoneally and could be found 
after 30 min in the aortic endothelium, supporting the systemic distribution of the EV 
administered by this route. More interestingly, mice groups receiving the EV showed 
thinner neointima in the grafted carotid, which was correlated with a decreased 
macrophage infiltration and decreased expression of IL-6 and MCP-1 in the graft [71]. 
Of note, the intraperitoneal administration route allows the loading of larger EV doses, 
which may represent an advantage compared to other routes of systemic 
administration [4]. However, injected EV are also rapidly diluted to unwanted sites due 
to the big area of the peritoneal cavity [72]. 
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2.1.3. EV oral administration 
Oral administration is the most convenient route for pharmaceutical products 
intake, due to ease of administration, facilitating patients’ compliance to treatment. 
However, in this route EV face important obstacles. The intestinal barrier, changes in 
pH along the gastrointestinal tract and the characteristics of the intestinal microflora 
are further aspects that EV need to overcome to reach their target tissue or organ. 
Rezaie et al. suggested that this type of administration is mostly successful for delivery 
in luminal epithelial surface of the gastrointestinal tissues than in other target tissues 
[72]. Comparatively to other routes of administration, few studies were published so 
far reporting EV administration by oral route. Moreover, the works published mainly 
report the administration of milk-derived EV. In 2015, Arntz et al. reported the first oral 
delivery of bovine milk-derived EV with effects in arthritis [73]. Researchers used two 
different mouse models of arthritis and tested the capacity of these EV to delay the 
appearance of the disease and the evolution of the inflammatory phenotype. After EV 
administration, by oral gavage or in drinking water, histology analysis confirmed the 
delay of the arthritis as well as a decrease of cartilage and bone marrow inflammation. 
Serum levels of pro-inflammatory cytokines were also reduced [73]. Agrawal et al. 
used EV from bovine milk for oral delivery of the chemotherapeutic drug Paclitaxel. To 
demonstrate the therapeutic effect of these vesicles, they used a female athymic nude 
mice model with lung tumor xenografts. Results showed a higher effect of drug-loaded 
EV on the inhibition of tumor growth, compared to control groups treated with PBS, the 
free drug or EV alone. Importantly, they observed a reduced systemic toxicity and 
inflammation when loaded EV were administered orally, comparing to their intravenous 
administration [74]. Thus, from this study, oral administration appears an adequate 
choice to decrease toxic side effects of EV systemic administration and to make EV-
based therapies more efficient. The same group reported similar observations for milk 
EV loaded with the anti-cancer drug curcumin [75]. Upon oral administration of these 
loaded EV in mice bearing cervical tumor xenografts, tumors had lower volumes 
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compared to control animals. However, curcumin could be found in lungs, liver and 
brain, in a dose dependent on EV dose administered [75].  
 
2.1.4. EV intranasal administration 
The intranasal route is also used for EV administration, with the first studies 
reporting this approach for the induction of a systemic immune response against air-
borne pathogens, using EV from infected macrophages [76]. Another study reported 
this approach to promote tolerogenic immune responses to air-borne allergens using 
bronchoalveolar lavage fluid-derived EV [77]. However, this route is also particularly 
interesting for the delivery of pharmaceutical products to the brain, either by entering 
the nearby circulation followed by crossing of the BBB, or directly through olfactory and 
trigeminal nerve cells [78]. Moreover, EV passage to circulation via the nasal route 
diminishes EV loss, because it avoids the intestinal and hepatic metabolism [79]. 
Indeed, this kind of administration showed great results in studies for Parkinson’s 
disease therapy in mouse models of this condition, having neuroprotective effects [43]. 
Furthermore, the EV intranasal administration was reported to be more effective in 
retaining the vesicles in brain tissue than their systemic administration via intravenous 
injection in the tail vein [80].  
Comparing different routes of administration, Yan et al. used EV from human 
umbilical cord MSCs in a murine model of hepatic oxidant injury, the CCl4-induced 
acute liver failure. EV administration was tested orally and by injection in the tail vein, 
with different doses being tested. Both investigated routes showed similar effects, 
which gives advantage to the oral route due to the ease of administration. The results 
demonstrated significant antioxidant effects in CCl4- and H2O2-injured cells. In addition, 
cell viability increased after EV administration. However, the mechanism underlying 
EV effect in hepatic oxidative stress remained unclear [81]. 
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It is important to note that the classification of systemic and local routes of 
administration is not entirely linear. There are routes of administration, like the 
intraperitoneal, the intranasal or the subcutaneous, that are most commonly 
considered for local delivery. However, they can also be employed in systemic 
delivery, depending on the specific situation. In the case of subcutaneous injection, it 
can be used for local or systemic delivery (as detailed in the next section), when 
intended to act far from the site of administration, achieving systemic circulation. 
Intraperitoneal administration is considered systemic, but it is mainly used to reach the 
gut, without necessarily going through the systemic circulation. Also, intranasal 
administration can be used to reach the systemic circulation, but it is mainly exploited 
due to its proximity to the brain. 
Altogether, the different routes of systemic administration have some common 
limitations. The distance and barriers that EV have to travel until reaching their target 
cells, implies that most vesicles do not reach the target, and instead accumulate in 
other organs. Common constraints influencing EV biodistribution include passage 
through physical barriers such as capillary endothelium, gastrointestinal epithelium 
and the blood-brain barrier, uptake by non-target tissues, including entrapment in their 
extracellular matrix, phagocytosis by immune cells, particularly macrophages, and 
clearance in urine. Ultimately, this implies that higher EV doses have to be 
administered in order to achieve the intended biological effect at the target tissue. One 
possible strategy to overcome these problems is to increase EV tropism to the tissue 
of interest. This may be achieved by EV functionalization with surface proteins binding 
ligands on target tissues. In fact, Tominaga and colleagues demonstrated that the 
transfection of surface proteins from donor cells in EV-producing cells functioned as 
strategy to harness EV with special tropism to the brain [82]. Thus, it remains a 
challenge in EV delivery to find the responsible proteins for different targets, in order 
to achieve natural organ tropism for EV. Another possible strategy to increase the 
chance of EV reaching their target tissue is their modification with “don’t eat me” 
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signals, such as CD47, which allows escaping the engulfment by immune cells [83]. 
Alternatively, to minimize the adverse effects of EV systemic administration, they can 
also be delivery directly to the target tissue. 
 
2.2. Strategies for EV local delivery 
Local drug administration is generally associated with reduced side effects [3], 
which will likely be the case also for EV. Furthermore, local administration of EV may 
overcome the often-reported low retention rates of the vesicles at specific target sites, 
compared to non-specific organs. 
One of the first studies reporting the local effect of EV dates back over a 
decade, to 2006, when Kim et al. demonstrated that EV derived from genetically 
modified murine bone marrow DC (overexpressing FasL), when administered locally, 
could resolve inflammation in a murine model of delayed-type hypersensitivity (DTH), 
and suppress the signals of arthritis in a collagen-induced arthritis mouse model. They 
administered EV via local injection in the footpad and via systemic intravenous 
injection, and concluded that both were effective in suppression of the DTH response 
and in the treatment of collagen-induced arthritis. However, EV injected locally were 
not detected in the animals liver or spleen, suggesting the effect of EV was not 
mediated systemically [84].  
In the cancer field, intratumoral injection of EV as an anti-cancer treatment 
strategy has been greatly explored. Some biodistribution studies reported unmodified 
EV to be unsuccessful in tumor-specific delivery upon i.v. administration [85] [86]. 
Alternatively, direct injection of EV into tumors has been shown to be a much more 
effective anti-tumor therapy. Indeed, the work of Smyth et al. suggests that the 
intratumoral injection of DIR-labeled EV derived from 4T1 cells allows much higher 
retention of the vesicles inside the tumor, than their i.v injection in the tail [87]. 
Furthermore, intratumoral EV injection has been reported as efficacious in tumor 
growth inhibition. In the work of Martins-Marques et al. [88], EV loaded with luciferin 
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and the chemotherapeutic agent doxorubicin, were injected in mouse tumors. Tumor 
growth was then monitored by bioluminescence imaging and a cytotoxic effect 
specifically in tumor cells was demonstrated. Interestingly, they concluded the 
presence of the gap junction protein connexin43 (Cx43) embedded in EV membrane 
improved the release of EV content into target cells, contributing to the reduction of 
cardiotoxicity of free doxorubicin injected systemically [88]. Intratumoral injection may 
be generally associated with reduced toxicity in non-target tissues. However, similar 
results using local or intravenous administration have also been reported [41].  
Although intratumoral EV injection is apparently more effective in tumor 
eradication, this type of administration is much more invasive than systemic 
administration, and thus unlikely to be as well accepted by patients [72]. In addition, it 
is not easily applicable for the treatment of tumors in deep body locations. However, 
injectable systems are also being developed that may facilitate delivery by minimally 
invasive surgery, and when surgery is required, for example for removal of the tumor, 
a delivery system could be implanted for the removal of cancer cells potentially 
remaining at the site. Indeed, a recent study by Palamà et al. leads us to speculate 
that an approach similar to the one they followed may be applicable for EV delivery. 
The authors reported the use of a poly-ε-caprolactone scaffold loaded with the anti-
inflammatory drug dexamethasone in the treatment of osteosarcoma, based on pre-
and-post-operative surgery [89]. Results demonstrated a sustained drug delivery and 
thus, a good strategy of localized tumor therapy.  
Another route of EV local administration often used is the subcutaneous 
injection. Investigations have shown that administration of EV by subcutaneous 
injection may be an effective anti-cancer treatment. An interesting study suggested the 
use of EV derived from M1-polarized macrophages as a cancer subcutaneous vaccine 
adjuvant [90]. A melanoma mouse model was used, and EV were injected 
subcutaneously in their right flank. To verify the EV distribution after administration, 
they were labeled with the lipophilic fluorescent dye Dil. Using an in vivo imaging 
 18 
system after animal’s sacrifice at 7 days after injection, EV were localized in inguinal 
and axillary lymph nodes near the injection local. This observation suggests that EV 
did not achieve systemic circulation in the lymphatics but mainly accumulated in lymph 
nodes near the place of injection, where they promoted an increase in the secretion of 
proinflammatory cytokines [90]. 
Since EV efficiency is dependent on their administration route, Hao et al. 
compared effects of EV administered via subcutaneous injection and via intradermal 
injection in antitumor immunity. This was performed in a mouse model with induced 
tumors in the tights. To monitor their distribution upon administration, EV were labeled 
and, despite the proximity of both injection routes to the tumor, by the intradermal 
route, labeled EV were detected in 3.8% of lymph nodes cells, against only 0.9% of 
cells when subcutaneous route was used. These results are in agreement with the 
mice survival rate upon the two different administration routes: intradermal route 
demonstrated to be more successful in antitumor immunity than subcutaneous 
administration [91]. Interestingly, the first clinical trials (phase I) using EV performed 
repeated injections of EV, derived from autologous dendritic cells (DC), into melanoma 
and non-small cell lung cancer patients using the intradermal (10% of the dose) and 
subcutaneous routes (90% of the dose). Nonetheless, only modest anti-tumoral effects 
were achieved [92]. More recently, a phase II clinical trial for the treatment of non-small 
cell lung cancer used conventional chemotherapy, combined with DC-derived EV for 
cancer treatment. In this trial, EV were administered exclusively by intradermal 
injection leading to an increase of 32% in the progression-free survival of patients [93]. 
Importantly, Dai and his team developed a Phase I clinical trial whereby EV derived 
from ascites of colorectal cancer, were subcutaneously administered to test their 
effectiveness in colorectal cancer treatment. Patients tested received EV only, or EV 
combined with the granulocyte–macrophage colony-stimulating factor (GM-CSF). Both 
were shown to be safe, but only patients who received EV with GM-CSF developed an 
antitumor cytotoxic T lymphocyte response [94]. 
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In the area of tissue repair and regeneration, subcutaneous injection of EV has 
also been reported. Komaki et al. injected subcutaneously placental tissue-derived EV 
into auricular wounds. They observed the capacity of this therapy to enhance 
angiogenesis in the murine auricle wound model [95]. In a mouse model of fat graft, 
animal flanks were subcutaneously injected with fat tissue, simultaneously with EV 
derived from normal or hypoxia pre-conditioned adipose tissue-MSCs, or with PBS. 
The subcutaneously administration of EV and fat tissue lead to an improvement in graft 
survival and integration, compared to control flanks injected with fat and PBS, 
suggesting the subcutaneous route of administration can be used for local EV 
administration and effects [96]. 
Zhang et al. demonstrated the ability of weakly intra-articular administrations of 
human MSC EV to repair critically-sized osteochondral defects in rat models. After 12 
weeks, regeneration was observed with hyaline cartilage and subchondral bone very 
similar to the original one [53]. As demonstrated by this study, short-term repeated 
doses of exosome should be administered during the regeneration process to achieve 
good results. This kind of EV delivery is not comfortable for a patient, and is pointed 
as one of the major drawbacks of this approach, for clinical application [97]. 
Although there are not many studies using this type of administration, 
intracavernous injection was performed by Chen and his team to demonstrate EV 
effects in erectile dysfunction (ED). The EV used were derived from adipose stem cells, 
and tested in a type 2 diabetes mellitus rat model. Results showed an improvement on 
ED in rats, by decreasing apoptosis of penile tissue. Despite positive results, many 
issues were unclear in this study, namely how long EV remained in the organ, what 
was the EV dose administered and the specific time of their administration, and what 
was the mechanism of action [98]. 
Depending on the therapeutic action intended and the tissues to be targeted, 
different routes of administration of EV can be chosen. Overall, this choice will 
determine the pharmacokinetics and biodistribution of administered EV.  
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2.2.1. EV loading into biomaterials 
Local and systemic delivery of free EV do not allow to control the retention at 
the target site, and consequently to achieve the concentration required for the 
therapeutic effects. Also, the release kinetics and the biodistribution of delivered EV is 
neither controlled nor fully clarified. 
This issue may be overcome by the incorporation of vesicles into appropriate 
biomaterial delivery systems that permit a timely and controlled release of EV in vivo. 
Controlled release will increase EV availability in the injury site for longer periods, 
maximizing their effect. In fact, EV have been used in combination with biomaterials of 
different types in a tissue engineering approach to treat several different lesions.  
Hydrogels constitute the class of biomaterials most used for EV delivery in vivo. 
They are very attractive for EV incorporation, since their mechanical properties can be 
tuned to a large extent by different techniques, including by using biocompatible cross-
linkers [99]. Thus, hydrogels with very small pores may be synthesized, providing a 
slow release rate of the vesicles. A gradual degradation of the material makes a 
prolonged release effective, and decreases side effects of bulk and fast EV 
administration, such as accumulation in non-target organs [100] [101]. Moreover, they 
can be easily modified with different moieties for improved nanoparticles attachment 
to the hydrogel, which may be translated to EV. Most importantly, hydrogels can be 
administered by different methods, including injection [99]. 
 In a recent study, Liu et al. tested the incorporation of EV isolated from cultures 
of human iPS-derived MSC in a photoinduced imine crosslinking hydrogel glue, useful 
for cartilage repair due to its biocompatibility, and its capacity of cartilage integration. 
This approach has many advantages when compared to other EV administration 
modes, such as the ability of retaining EV in the cartilage defect site or the ability of 
achieve an accurate fit and even distribution in irregularly shaped tissue defects. To 
monitor EV release from the glue, vesicles were labeled with the lipophilic fluorescent 
dye DiI prior to incorporation in the biomaterial, and release conditions were then 
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simulated in vitro. Released EV could be detected by nanoparticle tracking analysis 
and red fluorescence of Dil-labeled EV were found in the cytoplasm of chondrocytes 
also entrapped in the glue, suggesting a successful endocytosis of the released EV. 
With this approach, the authors could demonstrate a released of about 100 million 
EV/mL every day, resulting in a major therapeutic dose to the surrounding cells [97].  
EV delivery using biomaterial scaffolds has also been reported, particularly in 
recent studies. Huang et al. reported positive effects of EV derived from dental pulp 
cells on odontogenic differentiation in vivo and in vitro. In this study, EV were isolated 
and embedded in collagen sponges and included on the root canal space [102]. 
Another study compared the effects of exosome/β-TCP combination scaffolds with 
only pure β-TCP scaffolds in osteogenesis. Exosome-incorporating scaffolds were 
more effective in the bone repair on a rat critical-sized calvarial bone defect model, 
with large amounts of de novo bone formation [103]. In a recent work, Xie and 
colleagues functionalized decalcified bone matrix scaffolds with MSC-derived EV and 
investigated the angiogenic and osteogenic potential of these constructs in vivo. 
Regenerative potential of this scaffold was evaluated in a model of ectopic 
subcutaneous bone formation in nude mice. EV enhanced bone formation and 
increased vascularization in the grafts [104]. 
Chitosan-based materials have also been reported as delivery system for EV. 
Tao et al. reported controlled-release of EV derived from miR-126-3p-overexpressing 
synovium mesenchymal stem cells combined with a chitosan hydrogel. Chitosan 
without EV showed lack of angionesis. In vitro experiments showed an enhancement 
in human dermal fibroblasts proliferation. In vivo experiments with a diabetic rat model, 
confirmed increased reepithelialization, angiogenesis and maturation of collagen 
matrix. Thus, chitosan functions as a biomaterial with controlled-release capacity that 
leads to a potential approach when combined with EV from a modified cell line [105]. 
Another study reported similar results with chitosan/silk hydrogel loaded with gingival 
mesenchymal stem cells derived EV in in vivo experiments. As the previous study, a 
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diabetic rat was tested and positive effects on the diabetic rat skin wound repair were 
verified [106]. In an innovative approach, Huleihel et al. tested ECM bioscaffolds, 
produced by decellularization of connective tissue, as natural EV carriers. They found 
that EV naturally anchored in the native matrix could survive the decullarization 
protocols applied and, when implanted, could promote cell growth and proliferation, 
cell migration and cell differentiation. They also showed that EV have specific miRNA 
signatures associated to their source tissue, essential information to improve clinical 
applications [107]. 
Despite the good functional results reported so far, the use of carriers for EV 
delivery is still little explored, and advantages and disadvantages of these systems, 
compared with free EV administration, are not yet well characterized. For instance, 
studies addressing biodistribution and pharmacological kinetics parameters of EV 
entrapped in scaffolds are very limited. Another point that needs to be clarified is how 
the controlled release of the EV from these scaffolds is achieved in vivo. Many 
characteristics of scaffolds composition and structure may be tuned for optimal 
controlled release of EV from different origins, such as scaffold porous size, 
interconnectivity between porous, method of EV adhesion to the carrier, among others. 
Thus, in the near future, it is necessary to improve the design of carriers to use with 
EV.  
 
 
2.3. Future perspectives for EV controlled release: translation from the 
nanoparticles field 
The use of hydrogels or biocomposite scaffolds for the controlled delivery of 
EV, still requires more studies, namely to explore methods of EV incorporation in 
different matrices, to tune the rates of vesicle release in vivo to fit different applications. 
These issues have been extensively researched in the field of nanoparticles for drug 
delivery. Many studies have been published reporting the use of hydrogels or solid 
 23 
scaffolds combined with nanoparticles for the local controlled release of active 
compounds. Those studies may provide useful information on the development of 
similar systems to incorporate EV.  
For applications in the Tissue Engineering field, hydrogels and scaffolds doped 
with bioactive proteins, nano/microparticles of bioactive materials, or nanoparticles 
encapsulating active compounds have long been described. In many cases, these 
nanoparticles are liposomes or have a major lipidic composition, resembling EV in 
many of their physical properties.  
The capacity of self-assembled hydrogels to incorporate growth factors and 
liposomes, controlling their release, for instance by noncovalent interactions, makes 
them attractive for EV-delivery systems. Hydrogels showed no significant changes in 
mechanical properties upon vesicles incorporation and allowed bimodal drug release. 
When compared with controls, consisting of the individual factors solely loaded in the 
hydrogel, this system proved to be more efficient in promoting tissue regeneration, an 
effect mainly attributed to the controlled release of the incorporated factors [108]. 
Another study reported a hydrogel system with acidic liposomes for intratumoral 
injection in a tumor-bearing mouse model. A controlled release and prolonged action 
of these liposomes were reported, translating into an efficient antitumor action with 
decreased toxicity [109]. The controlled release of Fluconazole (FZL) loaded 
liposomes integrated in a hyalugel, as a novel ocular delivery system on male albino 
rabbits was used to overcome the limited penetration of FLZ in ocular fungal infection 
therapy, and results demonstrated an enhancing on corneal permeability and in 
sustained FLZ effect, as intended [110]. In addition, hydrogels decorated with 
nanoparticles and active compounds have also been used as coatings of materials 
used for biomedical applications. For instance, chitosan hydrogel films containing 
mesoporous silica nanoparticles loaded with ibuprofen were previously used to coat 
titanium surfaces, a material commonly used in orthopedic implants [111]. In our group 
chitosan and PGA have been combined as nanoparticles for drug loading [112], and 
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as a layer-by-layer systems, based on electrostatic interactions [113] for the delivery 
of molecules, like IFN- γ, when physiological pH disrupts the interaction between the 
layers [114]. Although EV have not been incorporated thus far in these systems, their 
negative charge should allow their incorporation based on electrostatic interactions, 
and their release when locally administered.   
In recent years, printing techniques applied to the biomedical field have greatly 
evolved, and bioprinting is nowadays one of the methods most explored in the 
development of novel drug delivery vehicles. Using this technique, liquid materials with 
active pharmaceutical drugs may be printed onto surfaces or be directly incorporated 
in the milieu of 3D scaffolds, in an oriented and controlled manner [115]. Many rigid 
scaffolds and hydrogels loaded with different compounds by bioprinting have been 
reported in the literature. As an example, Akagi et al. described the fabrication of a 
layer-by-layer composite of poly(L-lactide) and poly(D-lactide), loaded with ovalbumin 
or ovalbumin encapsulated in poly-γ-glutamic acid (PGA)/L-phenylalanine ethyl ester 
nanoparticles [116]. The printing of scaffolds with nanoparticles loaded with active 
drugs allow the construction of complex structures that ultimately control at several 
levels the release of the biologically active compounds at target sites. The 
incorporation of EV in bioprinted scaffolds has not reported so far. However, a recent 
study performed for the first time a polyethylene glycol (PEG) hydrogel incorporating 
red blood cell (RBC) membrane-coated nanoparticles (RBC-NPs) produced by a light-
based, rapid 3D bioprinting process. This is possible because this 3D bioprinting 
method is superior in resolution and speed when compared with traditional 3D printing 
[117].  
Interestingly, 3D-like meshes synthesized by electrospinning were also 
reported for the incorporation of drugs and nanoparticles, including liposomes [118]. 
More recently, Masek et al. used a porcine model to test an improvement of 
transmucosal delivery of macromolecular therapeutics. This approach involved 
electrospun nanofibrous reservoir layers and mucoadhesive layers as a system for 
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effective administration of PLGA-PEG nanoparticles. A high porosity and great pore 
interconnectivity made possible the slow clearance of the loaded nanoparticles [119].  
An alternative approach to increase EV bioavailability for therapeutic purposes 
could be achieved via their incorporation in osmotic pumps. Indeed, Hill and colleagues 
reported that incorporation of nanosuspensions of an undisclosed compound in the 
commercially available micro-osmotic pump Alzet® improved the availability of the 
compound in plasma upon pump implantation subcutaneously in mice [120]. In 
comparison with bolous subcutaneous injection of the nanosuspensions, osmotic 
pumps lead to a lower peak concentration of the compound of interest in the plasma, 
but which was maintained for a longer period of time, up to 7 days. Later on, Tian et 
al. showed it was possible to deliver nanostructured lipid carriers (NLC) incorporating 
fenofibrate, using osmotic pump tablets [121]. In this study, the release of integral NLC 
from the tablets could be observed in vitro, although great changes in their size 
occurred upon incorporation in the pumps. Importantly, in this approach NLCs were 
lyophilized to be incorporated into the osmotic pump, a process that seems to only 
mildly affect EV content, but not structure, being also suggested that their function is 
not affected provided lyophilization conditions are optimal [122].  
The use of foams has also been explored for the delivery of nanoparticle 
therapeutics, particularly for topical applications of high drug doses in large areas or 
cavities of the body [123]. In 2015, Tang et al. reported two foam-based platforms 
incorporating nanoparticles for their controlled released, that were responsive to 
temperature or moisture [124]. When translating this approach into the EV field, foam 
formulations compatible with EV lipidic composition will have to be sought, to avoid 
their lysis or loss of biological activity. Furthermore, the method of foam formation will 
also have to be carefully considered, as higher pressures may lead to vesicle 
mechanical disruption.     
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3. Conclusion 
EV, in particularly microvesicles and exosomes, have been increasingly tested 
for their therapeutical potential in different diseases. EV constitute an interesting option 
for drug delivery, because they are biocompatible, they can deliver many different 
cargo and target specific cells. Many in vivo studies, and even clinical trials, using EV 
for therapeutic purposes have been reported. However, the doses administered, the 
formulation of EV, and the route chosen for their administration greatly varies across 
studies. Administration techniques range from systemic to local, leading to different 
biodistributions and outcomes, including off-target effects, important parameters that 
have to be carefully taken into account to translate EV research into the clinics. A solid 
preclinical and clinical body of data behind EV-based therapies is still lacking, and 
many important questions remain unanswered. However, there is an obvious and 
strong movement towards the development of EV-based therapies. In order to 
minimize toxic action of EV in non-target organs, and to maximize the intended 
therapeutic effects, EV have been incorporated in biomaterials that can control their 
release. The future, will likely comprise more complex and tunable EV delivery 
systems, particularly using methodologies well established in the nanoparticles field, 
that are easily translatable to EV delivery.   
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